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ABSTRACT 
The DECAF Score : Prognostication Scoring System for Patients  
Hospitalised with Acute Exacerbations of Chronic Obstructive  
Pulmonary Disease 
 
Introduction : 
Chronic obstructive pulmonary disease (COPD) is the fourth most frequent 
cause of death. In patients getting admitted with acute exacerbation of COPD 
(AECOPD), identifying simple, immediately accessible and strong prognostic 
indicators will aid in management decision. 
 
Aim of the study : 
To assess the DECAF score as an optimal clinical tool for accurate In-hospital 
prognostication of patients admitted with acute exacerbation of chronic obstructive 
pulmonary disease. 
 
Materials and Methods : 
 90 patients admitted with primary diagnosis of AECOPD were included.  
Patients were scored according to the DECAF scoring system – Dyspnea, 
Eosinopenia, Consolidation, Acidemia and atrial Fibrillation.  The patients were 
followed during the entire hospital stay.    The clinical outcome was categorized as 
a)improved b) status quo c) mortality.  The role of DECAF score in predicting in-
hospital outcome was analysed. 
 
Results : 
 Out of 90 patients studied, 44 patients had DECAF score between 0-1 (low 
risk),  15 patients had a DECAF score of 2 (Intermediate risk) and 31 patients had a 
DECAF score between 3-6 (high risk).  In the high risk group (DECAF 3-6) there was 
higher mortality, longer hospital stay and increased need for use of ventilator.   
 
Conclusion : 
 The DECAF score incorporates indices routinely available and helps to stratify 
patients admitted with AECOPD into clinically relevant risk groups.  It aids the 
physician in taking management decisions.   
 
Key words:  
Acute Exacerbation of Chronic Obstructive Pulmonary Disease, DECAF 
score, Prognosis. 
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Chronic Obstructive Pulmonary Disease (COPD) is a preventable 
and treatable disease that is characterised by persistent airflow limitation 
which is usually progressive and associated with enhanced chronic 
inflammatory response in the airways and lung to noxious particles or  
gases.  Exacerbations and comorbidities contribute to overall severity in 
patients1.  COPD is the fourth  most frequent cause of death after 
Ischemic heart disease, Cerebrovascular disease and Malignancy. COPD 
is a common cause of morbidity and mortality worldwide.  The disease 
leads to huge economic and social burden which seems to be increasing 
day by day. The Global Burden of Disease Study projected that COPD, 
which is ranked sixth as a cause of death in 1990, will become the third 
leading cause of death in 20202. This increasing mortality is mainly due 
to increasing trend of smoking, reduced mortality from other  common 
diseases  and increasing longevity of world population.  
Acute Exacerbation of COPD (AECOPD) is an acute event 
characterised by worsening of patient’s symptoms that is beyond normal 
day to day variations and leads to a change in medication.  Exacerbations 
accelerate the rate of decline of lung function and are associated with 
significantly high mortality3. Another commonly used definition of 
AECOPD was given by Anthonisen and colleagues4.  Three cardinal 
symptoms have to be present in order to define an episode as acute 
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exacerbation: increased sputum quantity, altered sputum 
quality(increased purulence), and increased dyspnea. According to these 
criteria, an exacerbation can be classified into three types 
TABLE 1 : Types of AECOPD 
Type I (most 
severe) 
Type II Type III 
All three symptoms 
(i.e. increased 
sputum volume, 
increased sputum 
purulence and 
increased dyspnea). 
 
Any two  
symptoms 
present 
 
One symptom present plus at 
least one of the following: 
• An upper respiratory tract  
   infection in the past 5 days 
• Increased wheezing 
• Increased cough 
• Fever without an obvious 
source 
• A 20% increase in 
respiratory rate 
• Heart rate above baseline 
 
Exacerbations have a negative impact on patient’s quality of life, 
affect symptoms and lung function taking several weeks to recover from.  
In patients presenting with hypercapnic exacerbations, the in-hospital 
death rate is around 10%5.  If a patient is put on mechanical support 
during hospitalisation the death rate reaches 40% at one year after 
discharge6.  The mortality three years after discharge reaches 49%7.  The 
burden of COPD can be tackled by a comprehensive approach which  
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includes prevention, prompt diagnosis and immediate management of 
exacerbations. COPD exacerbations  are precipitated by respiratory tract 
infections8, air pollution9, congestive heart failure, pulmonary embolism 
and interruption of maintenance therapy.  The cause for about one third of 
exacerbations cannot be identified. When the number of exacerbations 
per year is two or more, then the COPD patient is called a “frequent 
exacerbator” 10. Acute exacerbations,  have a negative impact on the 
natural course of the disease. Roughly one to four decompensation 
episodes occur in a year in a COPD patient. Such exacerbations 
negatively influence the quality of life. These episodes lead to great 
healthcare and financial burdens. In a COPD patient 10 out of 100 times 
medical admissions are for an exacerbation episode and around 2% of all 
emergency department visits are due to exacerbations.  Almost  60% of 
the economic burden of the disease is related to exacerbation episodes, 
especially severe acute exacerbations needing hospitalisation11. 
Diagnosis of acute exacerbation of Chronic Obstructive Pulmonary 
Disease is mainly based on clinical presentation of increasing dyspnea, 
increasing quantity and change in quality of sputum. A panel of 
biomarkers are yet to be identified for diagnosing an exacerbation. 
Similarly sufficient clinical data does not exist to determine the adequate 
duration of hospitalisation in these patients. Multiple prognostic indices 
related to higher death rates in COPD like Forced Expiratory Volume in 
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one second12, Patient age13, Hypoxemia14,  Hypercapnia15, Comorbidity, 
Pulmonary hypertension, Body mass Index16,17, have been investigated. 
Studies assessing prognostic factors in AECOPD patients who are  
hospitalised have been performed infrequently.  Robust clinical tools 
which aid in management decisions have not been developed. Well 
established scores like BODE18 score exist to assess mortality risk in 
stable COPD. Prognostic tools derived for stable state disease have not 
been studied on patients requiring hospitalisation. Prognostic research in 
exacerbations needing hospitalisation has been limited.  There seems to 
be considerable difference in prognostic factors in acute exacerbation and 
stable COPD. There is need for identifying simple, easy to use, easy to 
obtain but strong predictors of in-hospital mortality. These predictive 
factors should also help in deciding the need for post-hospital care. 
J Steer et al 19 developed a simple prognostication tool in acute 
exacerbation of COPD – the DECAF score, that will help in deciding 
location of care, early stepping up of care and anticipation of need for 
ventilatory support. It helps the physician in informing the relatives and 
patients on prognosis and  risks associated with exacerbations.  Thus it 
will help in directing the most efficient use of resources and thereby 
reducing mortality and morbidity.  
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Dyspnea severity and Mortality: 
In COPD, the extent of breathlessness is assessed using the 
Medical Research Council Dyspnea(MRCD) Score. Compared to Forced 
Expiratory Volume in one second (FEV1), MRCD score for dyspnea 
appears to be  a better predictor of mortality20.  Its predictive value in 
exacerbations needing hospital admissions  has not been adequately 
studied. However there are few reports  to show that higher MRCD 
scores are predictors of both long and short term mortality. It has been 
shown that greater ‘functional dependence’ independently predicts 
hospital readmission and performance status. An important predictor of 
three month mortality following hospitalisation is a patient’s inability to 
manage self care. In those patients who survive upto discharge, long term 
mortality is higher if there is higher level of functional dependence. Thus 
severe disability strongly influences the management considerations of 
individual patients. When dyspnea assessment is combined with a 
measure of functional dependence, predictive ability of the traditional 
dyspnea scoring scale can be improved.    
J Steer et al21, in a retrospective study described an improved 
version of MRCD scale – the extended MRC Dyspnea score(eMRCD), 
which was better in identifying patients at risk of repeated hospitalisation 
when compared to  the MRCD scale though the latter is more frequently 
used. They studied a  large population of patients with acute exacerbation 
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of COPD. The ability of both  MRCD and eMRCD scores in  predicting 
in-hospital death and early admission were compared.   
Table – 2 Extended Medical Research Council Dyspnea Score 
Limitation due to breathlessness MRCD eMRCD 
Breathless only with strenuous exercise 1 
Breathless when hurrying on level / walking up a 
slight hill 
2 
Walks slower than peers, or stops when walking 
on the flat at own pace 
3 
Stops after walking 100m, or for a few minutes 
on the level 
4 
Too breathless to leave the house 5 . 
& independent in washing and / or dressing . 5a 
& dependent in washing and dressing . 5b 
  
In their study with 920 participants, 96 patients died in the hospital.  
The mortality rate for  eMRCD 5a was 17.3% (30/96). The mortality rate 
for  eMRCD 5b was 33.1% (47/96) (p=0.0012). In the non pneumonic 
AECOPD,  the in-hospital death rates for patients with eMRCD 5b was 
significantly more than those with eMRCD 5a with  p=0.048.  In patients 
with pneumonic AECOPD , there was similar association. However it 
was not statistically significant (p=0.069). The eMRCD 5b group had 
higher 28 day readmission rates compared to the eMRCD 5a group  
(p=0.044). The prognostic  ability of MRCD, eMRCD, and CURB-65 in 
assessing short term mortality were compared  using areas under 
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receiving operator characteristics curve. In the study population, the in-
hospital mortality was better predicted by  eMRCD when compared to 
MRCD (p=0.0012) and CURB-65(0.019). In the non pneumonic 
AECOPD group, eMRCD had better discrimination compared to both 
MRCD (p=0.057) and CURB-65 (p=0.053), though it was statistically not 
significant. In pneumonic exacerbation, eMRCD scored significantly 
better than CURB-65.  This study shows that when the traditional MRCD 
scale is extended  to take into account a person’s functional dependence 
(eMRCD), the predictive strength of the grading system is improved. 
eMRCD is better at  assessing both in-hospital mortality and subsequent 
need  for  readmission following discharge.  This grading system  helps to 
classify a subgroup of patients who are at higher risk for in-hospital 
mortality (33.1% with eMRCD 5b). Assessing the of severity of dyspnea 
in  patients  requiring hospitalisation for AECOPD is easy to perform. 
Dyspnea grade is a potent predictor of outcome and provides important 
information which could aid in management decisions.   
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Mortality and Eosinopenia. 
There are many studies that have assessed eosinophil counts, 
especially eosinopenia, as an indicator of infection, inflammation and 
bacteremia. The sample size in these studies is quite small and they have 
included heterogeneous populations. This may have led to contradictory 
results, thereby forming an important limitation for their interpretation. 
In 2003 Gil et al22, studied the role of eosinophil count in patients 
with  infection. They showed that presence of elevated total  leukocyte 
count  ( more than 10,000/mm3) along  with  low eosinophil count( less 
than 40/mm3) was significantly associated with the occurence of bacterial 
infections. Subsequently, Abidi et al23, studied eosinopenia as a marker  
of sepsis. They concluded  that  low eosinophil count may be used as an 
indicator of infection in routine medical practice. 
In a cohort24 of 2,311 patients with bacteremia, investigators found 
that when compared with normal eosinophil count,  eosinopenia 
(<50/mm3) was associated with a 4.77-fold increase in mortality.  When 
confounding factors were removed, persistently below-normal eosinophil 
count was found to be an independent but strong predictor of  mortality.    
Abidi et al23. evaluated  the role of eosinopenia in predicting in-
hospital mortality. The study was done in  patients admitted in Intensive 
Care , a large proportion of whom had infection. Eosinopenia was 
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strongly associated with  mortality at 28 days. In the multivariate 
analysis, the  hazard ratio was 1.8.   
Holland et al25 studied sixty six patients hospitalised with 
exacerbation of chronic obstructive pulmonary disease. Admission 
eosinophil count was obtained  in all 66 patients. The mortality rate in 
patients with eosinopenia at baseline was 17.4%. The mortality rate in 
patients with normal baseline eosinophil count was 2.4%. Mortality in 
eosinopenia was  significantly higher when compared to patients with 
normal eosinophil values at p=0.049. Similarly group with eosinopenia 
had significantly longer duration of hospital stay (8 vs 5 days p=0.005).  
These authors  concluded that besides routinely used indicators, low 
eosinophil count could be a used as an independent marker of disease 
severity and prognosis.  It has been shown in  animal models that in the 
presence of acute infection or inflammations, the leukocytes are diverted 
towards the formation of polymorphonuclear cells thereby leading to a 
low eosinophil count. Thus eosinopenia  occurs when the   body responds 
to acute infection. This is not dependent on adrenal glucocorticosteroids. 
In patients requiring intensive care, eosinopenia is an independent and 
useful marker of sepsis. Low eosinophil count occurring in the setting of 
acute exacerbation of COPD may actually be reflective of the extent of 
accompanying inflammatory response. 
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Coexistent pneumonia in acute exacerbation of COPD: 
When a known case of COPD develops typical symptoms of  an 
exacerbation episode due to community acquired pneumonia, there is 
always a doubt in the clinician’s mind which it is right to call such an 
episode as AECOPD. Exacerbations in COPD are frequently associated 
with radiographic consolidation. Doubts have always existed as to 
whether patients with AECOPD and coexistent consolidation be  actually 
diagnosed as AECOPD, with varying practices world wide. However 
patients with concurrent pneumonia were not excluded from  major 
national studies of COPD exacerbation and non invasive ventilation in the 
United Kingdom. In these studies,  concurrent pneumonic consolidation 
occurred in  16% and 34.2% respectively26,27. Further a conventional 
chest radiography may not be  highly sensitive in identifying 
parenchymal consolidation. It has been seen that in quite a few patients 
who had  an initially negative radiography,  subsequent more detailed 
evaluation revealed the presence of consolidation28.  
Patients with pneumonic exacerbations of COPD had the same 
socio-demographic profile and severity of underlying disease when 
compared to subjects with non-pneumonic exacerbations. However the 
former group had more  severe  clinical and physiological derangement29.  
In both pneumonic and non-pneumonic exacerbations, the severity of 
airway obstruction and pathogens involved are similar. Exacerbations 
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associated with pneumonia  should not be  treated as just  pneumonia, but 
need proper treatment of the AECOPD. Hence these patients will need 
continuous low flow oxygen,  parenteral steroids, nebulised 
bronchodilators. If hypercapnic respiratory failure occurs noninvasive 
ventilation should be given. This suggests that coexistent pneumonia 
helps to  identify  patients with a higher severity of  acute illness. It does 
not signify a different disease process30.  
  
Pneumonic and Non pneumonic acute exacerbations of COPD   
David Lieberman et al31  conducted a study in tertiary care  
Medical Centre in South Israel. Twenty three hospitalisations for 
pneumonic acute exacerbation of COPD (PNAE) and 217 hospitalisations 
for non pneumonic exacerbation of COPD (NPAE) were included. 
Patients with community acquired pneumonia were also included in the 
diagnosis of AECOPD due to following reasons. – 
1. Patients had clinical features which are consistent with accepted 
criteria for AECOPD. The clinician gets to know the occurrence of 
pneumonia only by radiographic evaluation. It is not rational to eliminate 
the diagnosis of acute exacerbation of COPD in such patients. It is more 
apt to say that these patients have pneumonic exacerbation. This 
strengthens the importance of combination of events. 
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2.  Most of the patients with AECOPD are managed on an out-
patient setup.  In such a scenario, chest radiographs are not routinely 
obtained. Hence elimination of patients with community acquired 
pneumonia is not practically possible.  They showed that compared to 
NPAE, patients with pneumonia had higher rates of hypoxemia, higher 
rates of hospitalisation(P=0.004), higher rates of sudden onset (P=0.005).  
Patients with PNAE also had higher rates of ICU admission (P=0.006),   
intubation(p=0.01),  in-hospital death (P=0.007) and longer  duration of 
stay in hospital(P=0.001). In PNAE, Viral and pneumococcal etiologies 
are more common.  
 
Table3 - Comparison of Hospital Factors Between Pneumonic 
AECOPD and Nonpneumonic AECOPD Groups 
Variable Pneumonic Non pneumonic 
  AECOPD AECOPD P value 
   (n=23) (n=217)  
Invasive ventilation 4(17) 10(5)  0.01 
Admission to ICU 6(26) 14(7)   0.006 
Mortality 3(13)  2(1)  0.007 
Hospitalization,days 7.9[8.3]  4.6[4.1]  0.001 
Readmission 2(10)  36(17) NS 
Recovery  within 30 days 16(80)  166(77)  NS 
Data are presented as No.(%) or No.[SD]. 
 
  
15 
 
 
Table 4 - Comparison of the frequency distribution of infectious 
etiologies between pneumonic AECOPD and  non pneumonic 
AECOPD Groups 
Etiology 
Pneumonic 
AECOPD 
(n=23) 
Nonpneumonic 
AECOPD 
(n=217) 
P 
Value 
Viral agents 
     Influenza virus type  A 
     Influenza virus type  B 
     Parainfluenza virus type 1 
     Parainfluenza virus type 2 
     Parainfluenza virus type 3 
     Adenovirus 
     Respiratory  syncytial virus 
     At least one of the above  
Bacterial agents 
     S pneumoniae 
     H influenzae 
     M catarrhalis 
     At least one of the above 
Atypical bacterial agents 
     Legionella spp. 
     M pneumonia 
     At least one of the above 
Agent  not  identified 
 
 
0(0) 
3(13) 
3(13) 
9(39) 
1(4) 
5(22) 
2(9) 
18(78) 
 
10(43) 
3(13) 
1(4) 
10(43) 
 
5(22) 
3(13) 
8(35) 
1(4) 
 
 
23(11) 
12(6) 
16(7) 
29(13) 
6(3) 
15(7) 
14(7) 
99(46) 
 
38(18) 
7(3) 
8(4) 
48(22) 
 
35(16) 
31(14) 
64(30) 
64(30) 
 
 
NS 
NS 
NS 
0.004 
NS 
0.03 
NS 
0.003 
 
0.006 
NS 
NS 
0.02 
 
NS 
NS 
NS 
0.001 
Data are presented as No.(%). 
 
J Steer et al21 showed that co-existent pneumonia is common in 
patients with acute exacerbation of COPD. It is also associated with high 
mortality rate. When there is simultaneous occurrence of AECOPD  and 
pneumonia, the mortality rates are higher than pneumonia alone. A total 
of 920 were  patients included in the study. Pneumonic AECOPD  
patients had longer hospital stay (seven days) compared to patients with 
non pneumonic AECOPD (six days, p<0.001).  The in-hospital death 
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rates for non pneumonic AECOPD(36/621)  was 5.8% whereas  20.1% 
with PNAE died in hospital(60/299).  28 day readmission rates for 
pneumonic AECOPD was 19.5% and non pneumonic AECOPD was 
18%. There was no statistical difference in readmission rates (P=0.62). 
Table 5 – pAECOPD and In-hospital mortality 
pAECOPD and CURB-65 In hospital mortal ity 
0-1 11% 
2 16% 
3-5  31.2% 
 
CURB-65 is often used to stratify patients with pAECOPD. It is 
frequently used to guide treatment in these patients. However it is clear 
from the data that CURB-65 is not an accurate predictor of  risk of 
mortality in this population.  When statistically analysed it is seen that 
CURB-65 performs moderately  with AUROC = 0.661.  eMRCD with 
AUROC = 0.759, performed better in predicting   short term (p=0.017) as 
well as post hospital follow up moratlity (p=0.040). Recent studies have 
shown that CURB-65 is a good predictor of in-hospital mortality in non 
pneumonic AECOPD.  From the above study it is clear that eMRCD has 
out-performed CURB-65 for all patients. 
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Acidemia and mortality : 
The frequency of hypercapnic respiratory failure in patients with 
AECOPD varies from 16-35% with overall mortality of 35-43%32. 
Hypoxia was a common condition on hospital admission as well as 
hypercapnia. Respiratory acidosis (arterial pH ≥ 7.35 and/or PCO2  
≤ 6.0kPa, 45 mm hg) is an indication for ventilator support in AECOPD1. 
It can be provided  either by noninvasive (by nasal or facial mask) or 
invasive ventilation (by oro-tracheal tube or tracheostomy). Mechanical 
ventilation decreases acute respiratory acidosis. It reduces tachypnea, 
work of breathing, severity of  dyspnea and duration  of  stay in hospital . 
  
Karin H. Groenewegen et al33 studied a  total of 171 patients 
admitted with AECOPD. The in-hospital death rate was 8%. The death 
rate at 1 year of follow up was 23%. The in-hospital mortality rate for 
patients requiring intensive care management was comparable at 6%. 
However in patients admitted to the ICU for respiratory failure, the 1-year 
follow up mortality rate was significantly higher at  35%. The 
multivariate Cox proportional hazards model was used to determine 
independent predictors of survival. Variables included in the regression 
model were age, sex, FEV1, PO2, PCO2, body mass index, long-term use 
of oral corticosteroids, comorbidity index, and hospital readmissions. The 
maintenance use of oral glucocorticosteroids (relative risk [RR], 5.07; 
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95% confidence interval [CI], 2.03 to 12.64), PCO2 (RR, 1.17; 95% CI, 
1.01 to 1.38), and age (RR, 1.07; 95% CI, 1.01 to 1.12) were 
independently related to mortality. They showed that when the 
characteristics of ICU patients and non-ICU patients were compared, ICU 
patients had higher PCO2 and lower pH values. 
 
 
Table 6 - Characteristics of Patients Transferred to ICU 
Characteristics ICU Patients (n=17) 
Non-ICU 
Patients 
(n=154) 
p Value 
Age, yr 73.4±6.5 70.4±8.6 NS 
FEV1,% predicted 34.2±12.2 39.1±15.4 NS 
PaO2, kPa 8.0±5.0 7.4±2.7 NS 
PaO2, kPa 9.3±2.7 6.5±1.9 0.0001 
PH 7.31±0.9 7.39±0.7 0.0001 
BMI,kg/m2 26.1±6.5 24.1±4.2 NS 
Comorbidity index 1.50±0.89 1.55±0.90 NS 
Corticosteroid use, 
No. 
2 15 NS 
Length of stay, days 9.45 16.88 0.005 
Values given as mean±SD, unless  otherwise  indicated. NS=not  
significant. 
 
Chronic alveolar hypoventilation leads to hypercapnia. Thus 
hypercapnia is reflective of severity of the respiratory disease. Hence 
compared to patients with normoventilation, those with persistently 
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elevated pCO2 have poor prognosis. Patients with chronic hypercapnia 
constituted a major chunk of the study group.  
In one study34, patients with severe COPD with at least one 
hospital admission for hypercapnic respiratory failure were compared to 
patients who had been treated for unresectable non-small cell lung cancer. 
The results of this study showed that COPD patients had significantly less 
ability to perform the activities of daily life, lower physical, social and 
emotional functioning than did patients with non-small cell lung cancer. 
This study confirms that COPD patients do not receive the necessary 
palliative care that is needed. 
Steer et al19 showed in their study that arterial pH was statistically 
lower in patients who died in hospital compared to those who survived till 
discharge (pH <7.3 odds ratio (95% CI) 2.68(1.41 – 5.09) p=0.003).  
 
Atrial fibrillation and COPD: 
COPD is associated with high risk of cardiac arrhythmias. 
Hypoxemia35, acidosis36, corpulmonale37, coexisting ischemic heart 
disease38 have been considered major causes of arrhythmias in COPD. 
The type and risk of  arrhythmias occurring in a COPD patient is 
determined by severity of the disease.  Supraventricular tachycardias are 
the most common arrhythmias occuring during exacerbations . However, 
even in patients with stable COPD the incidence of cardiac arrhythmias is 
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considerable. Commonly  atrial fibrillation (AF) is seen in patients 
hospitalised for exacerbations.  AF is by far the most common arrhythmia 
in the elderly population.   
P.Buch et al39 analysed data from 13,430 males and females.  The  
participants were taken from the Copenhagen City Heart Study. None of 
the subjects had previous myocardial infarction. Re-examination was 
done after 5 years to look for new arrythmias. Multivariate analyses were 
used with adjustment for cardiopulmonary risk factors. At the time of 
hospitalisation 290 cases of AF were diagnosed (2.20%).  There were 62 
new cases of AF at 5-yr follow-up (0.58%). Risk of new AF at re-
examination was 1.8-times higher for FEV1 between 60–80% of 
predicted compared with FEV1 > 80% after adjustment for sex, age, 
smoking, blood pressure, diabetes and body mass index. The risk of 
hospitalisation for AF was 1.3-times higher for FEV1 between 60–80% 
and 1.8-times higher for FEV1<60% compared with FEV1 ≥80%, when 
additional adjustment was made for education, treatment with diuretics 
and chest pain at activity. The authors concluded that reduced lung 
function is an independent predictor for incident atrial fibrillation.   
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Table 7.Presence of atrial fibrillation (AF) at baseline, at re-
examination and at incident hospitalizations according to lung 
function 
                                        FEV1% predicted 
 <60% 60-80%  80% 
At baseline 
     Subjects n  
 
1259 
 
 
3904 
 
 
8351 
 
     Presence of AF 15(1.20) 32(0.82) 31(0.37) 
At re-examination  
     Subjects n 
 
809 
 
2947 
 
6910 
     Presence of AF 9(1.11) 25(0.85) 28(0.41) 
At hospital admission 
     Subjects n 
 
1167 
 
3699 
 
8315 
     All cases of AF 47(4.03) 96(2.60) 147(1.77) 
     AF as main diagnosis 46(3.94) 28(0.76) 19(0.23) 
Data are presented as n(%) unless otherwise stated. FEV1 predicted :  
forced expiratory volume in one second % predicted. 
 
The mechanism connecting reduced lung function with AF is not 
clear. Recent observations40 have revealed that ectopic beats initiating AF 
often originate in the walls of the pulmonary veins. It is possible that this 
could be triggered by changes in gas composition or pulmonary 
hypertension. Hypoxia and corpulmonale could only account for some of 
this effect since the relationship was also found in subjects with mild to 
moderately reduced FEV1. Reduced lung function has been shown to be 
an independent predictor of IHD and of stroke, and it is possible that the 
biological mechanism for development of AF could be linked to 
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atherosclerosis via a common pathway of development of vascular and 
airways disease, e.g. foetal or early childhood exposure41.  
 
Predictors of outcome in acute exacerbation of COPD: 
Roche et al30 studied COPD patients visiting emergency 
department due to exacerbation. They identified simple, accessible but 
strong predictors of in-hospital mortality and the need for post hospital 
support.  They found 3 simple clinical criteria that were important 
predictors of  in-hospital death. 
The criteria were  
1. Age 
2. Clinical severity at entry 
3. Baseline dyspnea grade 
Factors considered in clinical severity were  
1. Cyanosis,  
2. Lower limb edema,  
3. Asterixis,  
4. Neurological impairment,  
5. Use of inspiratory accessory muscles, 
6. Expiratory use of abdominal muscles. 
 
The following table presents the results of Multivariate logistic regression 
analysis: 
  
23 
 
TABLE - 8 : Odds ratio for death and need for post-hospital support 
at discharge on multivariate logistic regression analysis 
 Risk of death Post-hospital support need 
Females versus males 
Age≥70yrs 
 
4.5(1.6-12.1) 
2.2(1.4-3.4) 
3.4(2.1-5.5) 
Clinical signs of severity 
at entry 
  
Cyanosis 1.5(0.7-3.0) 1.6(1.0-2.6) 
Neurological impairment 5.1(2.4-10.8) 3.3(1.6-6.7) 
Lower limb oedema 1.0(0.4-2.0) 1.0(0.5-1.5) 
Asterixis 1.7(0.6-4.3) 0.7(0.3-1.7) 
Use of inspiratory 
accessory muscles 
2.6(1.1-6.2) 1.6(1.0-2.7) 
Expiratory use of 
abdominal muscles 
0.9(0.4-1.9) 1.2(0.7-2.0) 
Baseline dyspnea grade   
0-1 1.0 1.0 
2-3 3.6(0.7-16.5) 1.3(0.7-2.2) 
4-5 6.5(1.4-29.3) 2.0(1.1-3.6) 
 
Data are presented as odds ratio (95% confidence interval) when all 
clinical signs of severity are individually integrated into the model. 
 
In 2001, The American College of Physicians and The American 
Society of Internal Medicine conducted an evidence based process42. 
Only 11 studies had been conducted to identify predictors of in-hospital 
mortality. In the 5 largest studies with multivariate analysis (N=322-
3050), the independent predictors of in-hospital deaths were 
1.  Age 
2. Acute physiology score 
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3. Body mass Index 
4. Functional status before exacerbation 
5. PO2/Inspiratory oxygen fraction ratio. 
6. Need of mechanical ventilation 
7. Serum Albumin 
8. Sodium levels 
9. Cardiac comorbid conditions 
None of these studies provided a simple prediction tool to aid in 
management decisions. 
Yan Chang et al43 conducted a  study to assess all cause death in 
COPD. Cross-sectional study of patients with the discharge diagnosis of 
COPD, utilizing the Premier Perspective database was carried out. 
Patients aged 40 years and above were selected if they had a primary 
discharge diagnosis of COPD. All data analyses were based on individual 
level. Predictors for mortality were identified by multiple logistic 
regressions. Bonferroni correction for multiple logistic regression models 
was adapted to control family-wise errors. After excluding outliers, the 
bivariate logistic regressions were conducted between mortality and the 
independent variables.  From the results of the univariate analyses, the 
mortality risk of patients of COPD increased by 4% for every increase in 
age by 1 year and female patients were 19% less likely to die compared to 
male patients. The highest risk of mortality was in the patients who were 
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Asian (odds ratio [OR] = 1.65; confidence interval [CI] = 1.02-2.65), had 
insurance (OR=3.31; CI=2.63-4.16), were admitted with elective 
admission (OR=1.95; CI=1.67-2.27), had extreme severity of illness 
(OR=38.26;  CI=29.61-49.43), had extreme risk of mortality (OR=88.56; 
CI=67.97-115.39), and were assigned with Deyo-adapted Charlson Index 
score of 4 and above(OR=2.98; CI=2.50-3.55). Elixhauser comorbidities 
including valvular disease(OR=1.50; CI=1.07-2.10), other chronic lung 
disease (OR=7.62; CI=4.53-12.80), renal failure (OR=6.39; CI=3.03-
13.46), metastatic cancer(OR=3.24; CI=2.45-4.27), solid tumor without 
metastasis (OR=2.10; CI=1.66-2.67), and weight loss (OR=5.26; 
CI=4.34-6.37) were more likely to happen to patients who died than who 
survived; however, comorbid conditions such as hypothyroidism  
(OR=0.82; CI=0.61-0.98) and depression  (OR=0.68; CI=0.54-0.85) were 
associated with decreased risk of morality. Oral/parenteral corticosteroids 
(OR=0.76; CI=0.66-0.88) and antibiotics (OR=0.65; CI=0.56-0.75) had 
Odds Ratio less than 1.0, which indicated that they had a protective effect 
on mortality.  
John Steer  et al19, developed a robust clinical prediction tool. He 
studied a large population of   COPD patients getting hospitalised with 
exacerbations. 920 patients from diverse geographic locales were 
recruited.  Socio-demographic and clinical profile collected. They aimed 
at developing a simple but easily usable prognostic tool.  The strongest 
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five categorical variables selected and relative weights assigned 
according to regression co-efficient. Thus Dyspnea, Eosinopenia, 
Consolidation, Acidemia and Atrial fibrillation- The DECAF score was 
developed. DECAF score performed better for prediction of in-hospital 
mortality than other predictive instruments in AECOPD like Acute 
Physiology And Chronic Health Evaluation II prognostic index, the 
COPD and Asthma Physiology Score and BAP 65 score. The area under 
DECAF score ROC curve for predicting in hospital mortality was 0.86 
(95% CI– 0.82 to 0.89) 
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AIMS AND OBJECTIVES 
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Aims of the study: 
 
 To assess the DECAF score as an optimal clinical tool for accurate 
In-hospital prognostication of patients admitted with Acute Exacerbation 
of Chronic Obstructive Pulmonary Disease. 
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METHODOLOGY 
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Subject selection: 
 
Patients getting admitted to Rajiv Gandhi Government General 
Hospital (RGGGH) with symptoms of acute exacerbation of  Chronic 
Obstructive Pulmonary Disease (COPD) were selected.  
A patient was diagnosed  to have AECOPD if 
1. Age was above 35  years and 
2. History of exposure to risk factors 
 Smoking history of >10 cigarette pack 
 Smoke from home cooking and heating fuels 
 Occupational dusts and chemicals and 
  3. Spirometric evidence of airflow obstruction (forced expiratory 
volume in one second (FEV1)/forced vital capacity(FVC) <0.70 without 
significant reversibility) when clinically stable within last two years 
PLUS presence of any one of the following  
 worsening of dyspnea above normal day to day variations 
 increased quantity of sputum production 
 increased purulency of sputum. 
 Inclusion criteria 
 Patients admitted with primary diagnosis of acute exacerbation of 
chronic obstructive pulmonary disease 
 Age ≥ 35 years 
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Exclusion criteria 
1. Patients in whom the primary reason for admission was other 
than acute exacerbation of COPD were excluded from the study. Hence 
patients with the following diseases were excluded from our study 
 Bronchial Asthma-acute exacerbation 
 Bronchiectasis-infective exacerbation 
 Interstitial Lung Diseases-exacerbation 
 Lung cancer 
 Pneumothorax 
 Congestive cardiac failure 
 Acute on chronic decompensated liver disease 
 Acute on chronic decompensated renal disease 
 Psychiatric illness 
All of these exclusion criteria were left to the clinician’s discretion 
in order to ensure that the real life nature of the study was respected. 
 2. Previous inclusion in the study. 
Study centres 
The study was conducted at a premiere tertiary care institute - 
Rajiv Gandhi Government General Hospital, Park Town, Chennai 
Study design 
 The study was a prospective study. 
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 No specific intervention was carried out. 
 Consecutive patients admitted with the diagnosis of acute 
exacerbation of COPD during the study period were included in the 
study . No specific method of randomisation was used. 
 No controls were used in the study 
Study period: 
18 months  March 2013 – September 2014 
Data collection 
The following were assessed in our study in patients with Acute 
Exacerbation Chronic Obstructive Pulmonary Disease (COPD) 
 Socio-demographic and clinical data 
 Details of comorbidity 
 Complete blood count and absolute eosinophil count at admission 
 Arterial blood gas results at admission 
 Chest radiograph  
 Electrocardiogram 
Methodology 
  90 consecutive patients admitted with the diagnosis of acute 
exacerbation of COPD satisfying our inclusion and exclusion criteria 
during the study period were included .Socio-demographic and clinical 
data  of the study subjects were collected on admission. Breathlessness 
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was graded according to the extended Medical Research Council (MRC) 
dyspnea (eMRCD) Score21. This subdivides patients too breathless to 
leave the house unaided (traditional MRCD 5) into those who are able to 
independently manage washing and/or dressing (eMRCD 5a) and those 
and those requiring assistance with both (eMRCD 5b).  Details of 
comorbidity  were obtained from the clinical notes. Cardiac assessment 
was done by cardiologists. Complete blood count, absolute eosinophil 
count and arterial blood gas results performed at the time of admission 
were recorded. Chest radiograph was assessed by the treating physician to 
look for new consolidation. The presence of atrial fibrillation was 
confirmed by ECG at the time of hospital admission. The patients were 
followed  during the entire hospital stay. Treatment was individualised 
for each patient. The investigator did not interfere with the treatment.  
Patients were scored according to the DECAF scoring system, wherein 
the following parameters are given points, 
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Table – 9: The DECAF Score 
 
Variable Score 
Dyspnea 
                                 eMRCD 5a  
                                 eMRCD 5b  
 
1 
2 
Eosinopenia (<50cells/mm3) 1 
Consolidation 1 
Acidemia (pH <7.3) 1 
Atrial fibrillation 1 
Total score 6 
 
DECAF: Dyspnea according to eMRCD, extended MRC dyspnea, 
Eosinopenia, Consolidation, Acidemia and atrial Fibrillation;. 
 
The clinical outcome was categorised as 
a) improved  
b) status quo  
c) mortality.  
“Improved” is clinically defined as subjective sense of 
improvement and objective improvement in dyspnea scoring.  “Status 
quo”  refers to patients who get discharged against medical advice and 
whose clinical condition at the time of discharge does not  
fit into the other two groups. The results were statistically analysed. 
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Extended Medical Research Council grades (eMRC) 
 
Dyspnea is a complex subjective sensation. Quantification of 
dyspnea is a difficult task. However it is necessary to do so for research 
purposes. Fletcher and his colleagues developed a short questionnaire 
while studying the pulmonary symptoms of Welsh coal miners at the 
Medical Research Council Pneumoconiosis Unit in the early 1940s. The 
questionnaire allowed the placement of a numeric value on the exercise 
capacity of each member of the study population. The questions were 
published in 1952. It was later developed into the MRC breathlessness 
scale47. The MRC breathlessness grades do not quantify breathlessness 
like the Borg scale or visual analogue scales. Instead, it quantifies the 
disability associated with breathlessness by identifying when 
breathlessness occurs or by quantifying the associated exercise 
impairment. There is a strong agreement between observers recording 
MRC dyspnea grades. The grades correlate well with other dyspnoea 
scales, lung function measurements and with objective measures of 
disability such as six minute walking distance. J Steer et al21 expanded the 
traditional MRC Score to develop extended Medical Research Council 
(MRC) dyspnea (eMRCD)  Score, this subdivides patients too breathless 
to leave the house unaided (traditional MRCD 5) into those who can 
independently manage washing and/or dressing (eMRCD 5a) and those 
requiring assistance with both (eMRCD 5b). The eMRCD Score is more 
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strongly associated with inhospital mortality than the traditional score. 
The patients were asked to choose the description that best suited their 
condition. 
 
Absolute eosinophil count: 
Hingleman’s solution stains the eosinophils , lyses the red cells and 
other leukocytes. 0.33ml of diluting fluid is mixed with 0.04ml of blood 
and kept for 10 minutes. The counting chamber is charged. Fuchs 
Rosenthal chamber with a depth of 0.2mm and a ruled area of 16 sq mm 
used. The cells in all 16 squares are counted under low power objective 
with 10X eyepiece.  
   Absolute eosinophil count = no. of cells counted x dilution 
          area counted x depth. 
   Eosinopenia is defined as absolute eosinophil count < 50/microlitre. 
 
Arterial blood gas analysis: 
For arterial blood gas analysis ABL80 FLEX analyser was used. 
ABL80 FLEX analyzer consists of the analyzer, a multi-use disposable 
sensor cassette and a solution pack. 2ml blood from radial artery or 
femoral artery is collected in ABG syringe. The tip of the inlet probe is 
fully immersed in the  sample.  The ABL80 FLEX CO-OX analyzer with 
OSM software configuration aspirates a sample volume of approximately 
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65 µL for each measurement. This volume is automatically aspirated into 
the analyzer during the sample analysis procedure. The results are 
displayed after the analysis. 
 
Electrocardiogram: 
The presence of atrial fibrillation on ECG was diagnosed with the 
help of following findings 
 Irregularly irregular rhythm. 
 Absence of P waves. 
 Absence of an isoelectric baseline. 
 Varying ventricular rate. 
 QRS complexes usually  < 120 ms unless pre-existing bundle 
branch block, accessory pathway, or rate related aberrant 
conduction. 
 Fibrillatory waves may be present and can be either fine (amplitude 
< 0.5mm) or coarse (amplitude >0.5mm). 
Pulmonary Function Testing : 
Patients who had spirometric evidence of airway obstruction (% 
FEV1<70%) without reversibility were included in the study. Spirometry 
is a physiological test that measures how an individual inhales or exhales 
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volumes of air as a function of time. Spirometry is done as per the 
American Thoracic Society recommendations. The appropriate technique 
of spirometry has to be demonstrated to each patient individually before 
the start of procedure. The patients are asked to inhale rapidly and 
completely upto Functional Residual Capacity (FRC). The patients are 
instructed to hold the mouth piece in their mouth, sealed tightly by their 
lips. Care has to be taken to prevent occlusion by tongue. Patients are 
asked to blast out air without any hesitation and are asked to completely 
exhale. Throughout the procedure, patients should be coached using body 
languages and phrases. The testing has to be done in sitting position and 
nose clips are used. Acceptability and repeatability criteria as 
recommended by ATS48 are  
 
WITHIN-MANOEUVRE CRITERIA 
 Individual spirograms are “acceptable”if 
 They are free from artefacts  
  Cough during the first second of exhalation 
  Glottis closure that influences the measurement 
  Eary termination or cut-off 
  Effort that is not maximal throughout 
  Leak 
  Obstructed mouthpiece 
 They have good starts 
  Extrapolated volume <5% of FVC or 0.15 L, whichever is greater 
 They show satisfactory exhalation 
 Duration of ≥ 6 s (3 s for children) or a plateau in the volume-time 
curve or  if the subject cannot or should not continue to exhale. 
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Between-manoeuvre criteria 
 After three acceptable programs have been obtained, apply the 
following tests. 
  The two largest values of FVC must be within 0.150 L of each 
other 
  The two largest values of FEV1 must be within 0.150 L of each 
other 
 If both of these criteria are met, the test session may be concluded 
 If both of these criteria are not met, continue testing until 
  Both of the criteria are met with analysis of additional acceptable 
spirograms or 
  A total of eight tests have been performed (optional) or 
  The patient/subject cannot or should not continue 
 Save, as a minimum, the three satisfactory manoeuvres. 
 
The test is then repeated after administration of salbutamol through 
nebulisation to see for reversibility 
 
Statistical analysis 
Statistical analysis was done using the SPSS softwares . 
Significance of correlation between variables was assessed using p value. 
A correlation was considered to be statistically significant if its p value 
was less than 0.05.  
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RESULTS 
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Age distribution: 
A total of 90 patients were included in our study as per our patient 
selection methods, inclusion and exclusion criteria.  The age group of our 
patients in our study ranged from 37 to 82. The mean age of the study 
population was 59.6 with a standard Deviation of 10.6. The number of 
patients in the age groups ≤40, 40-50, 50-60, 60-70, 70-80, >80 were 3 
(3.3%), 20 (22.2%), 25 (27.8 %), 26 (28.9%), 15(16.7%) and 1(1.1%) 
respectively. 
 
 
Age ≤40 40-50 50-60 60-70 70-80 >80 
No 3 20 25 26 15 1 
 
Fig 1: Age distribution 
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Age Distribution
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Gender distribution: 
Out of the 90 patients in the study, 81 are male and 9 are female. 
Thus males accounted for 90% of our study population while females 
accounted for 10%. 
 
 
Gender Male Female 
No 81 9 
 
Fig 2: Gender Distribution 
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Comorbidity: 
In the study population, 47 did not have any comorbid illness.  The 
most common comorbidity among the study population is Pulmonary 
Tuberculosis Sequalae.  Among ‘others’ 4  patients had coronary artery 
disease, 2 patients had obstructive sleep apnea, 3 patients had connective 
tissue disorders, 3 patients had hypersensitivity pneumonitis 
 
 
Comorbidity No 
Systemic hypertension 6 
Diabetes mellitus and Systemic hypertension 1 
PTB sequalae 22 
Chronic kidney disease 2 
Other 12 
Nil 47 
Total  90 
Fig 3 : Comorbidities 
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Presence of cor pulmonale: 
Out of 90 patients included in the study 22 (24.4%)  patients had 
corpulmonale as evidenced on echo. Out of them 9 (10%) patients had 
mild pulmonary hypertension (PHT), 2 (2.2%) patients had moderate 
PHT, 11 (12.2%)  patients had severe PHT.  
 
Corpulmonale No 
No  68 
Mild PHT 9 
Moderate PHT 2 
Severe PHT 11 
Total 90 
 
Fig 4 : Corpulmonale 
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Dyspnea  grading: 
The patients in the study were graded according to the extended 
Medical Research Council score. Accordingly, 33 patients had eMRC 
grade 4, 22 patients  had eMRC grade 5a and 35 patients had a score of 
5b. In terms of percentage, the distribution of patients in grades 4, 5a and 
5b was  36.7, 24.4 and 38.9 respectively. 
 
Dyspnea grade eMRC No 
4 33 
5a 22 
5b 35 
 
 
Fig 5 : Dyspnea Score 
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Presence of Eosinopenia: 
Eosinopenia was defined as an absolute eosinophil count of less 
than 50/mm3. 6 out of 90 patients had eosinopenia. Hence 6.7% of the 
study population had low eosinophil count. 
 
Eosinopenia No 
Yes 6 
No 84 
 
Fig 6 : Eosinopenia 
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Presence of Consolidation: 
Assessment of chest radiographs of patients at admission to 
confirm the presence of consolidation was done.  Accordingly 28 (31%) 
patients had consolidation on chest radiograph. 
 
 
 
 
Consolidation No 
Yes 28 
No 62 
 
 
Fig 7 :  Consolidation 
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Presence of Acidemia: 
Acidemia is defined as the presence of arterial blood gas pH<7.30.  
24 patients (26.6%) had acidemia. 
 
 
 
Acidemia No 
Yes 24 
No 66 
 
Fig 8 : Acidemia 
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Presence of Fibrillation: 
Presence of atrial fibrillation was confirmed  with the presence of 
admission electrocardiogram. Accordingly 4 ( 4.4%) patients had atrial 
fibrillation, while the remaining 86 did not have fibrillation. 
 
 
Atrial Fibrillation No 
Yes 4 
No 86 
 
 
Fig 9 : Atrial Fibrillation 
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THE DECAF SCORE: 
Each patient was scored using  DECAF score – where dyspnea 
eMRC grade 5a gets 1 point, dyspnea eMRC grade 5b gets 2 points, 
others parameters, namely Eosinopenia, Consolidation, Acidemia, atrial 
Fibrillation get 1 point each. We divided the population into three groups 
namely low risk, intermediate risk and high risk with the groups getting 
DECAF score of 0-1, 2 and 3-6 respectively. 
 
44 patients had a DECAF score between 0-1, 15 patients had a 
DECAF score of 2 and 31 patients had a DECAF score between 0-6. In 
terms of percentage this is 48.9%, 16.7% and 34.4% respectively. 
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DECAF score No 
0-1(low risk) 44 
2(intermediate risk) 15 
3-6(high risk) 31 
 
Fig 10 : DECAF score 
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Duration of hospital stay : 
The average duration of hospital stay for the study group was 7 
days.  The length of hospital stay was divided into four groups- <5 days, 
5-10 days, 10-15 days, >15 days.  32 (35.6%) patients had hospital stay 
lesser than 5 days, 32 (35.6%)patients had hospital stay between 5-10 
days, 23(25.6%) patients  had hospital stay between 10-15 days, 3 (3.3%) 
patients stayed in hospital longer than 15 days 
 
Hospital stay No 
<5days 32 
5-10 days 32 
 10-15 days 23 
>15 days 3 
 
Fig 11 : Hospital Stay 
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Outcome: 
  The mortality rate for the study population was 10 out of 90 
(11%). 75 patients “improved” at the time of discharge with “improved” 
being clinically defined as subjective sense of improvement and objective 
improvement in dyspnea scoring, 10 patients died in the hospital, 5 
patients were discharged against medical advice whose clinical condition 
could not be defined as ‘improved’ or deteriorated at the time of leaving 
the hospital. 
 
DECAF score No 
Improved 75 
Mortality 10 
Status Quo 5 
 
Fig 12 : Outcome 
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Use of ventilator: 
Out of the 90 patients 14(15.6%) were put on ventilator, 6 were put 
on Non invasive ventilation and 8 were put on Invasive ventilation. 
 
 
Use of ventilator No 
Yes 14 
No 76 
 
 
Fig 13 : Use of Ventilator 
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Age and outcome:  
The mortality in the age groups 40-50, 50-60, 60-70,70-80 is 
4,4,1,1 respectively. When age was taken as scattered variables, older 
patients showed higher mortality. However there is no statistically 
significant association between the age and outcome,P≥0.05(P=0.800). 
 
 
Age Vs Outcome Improved Moratlity Status Quo Total 
≤40 3 0 0 3 
40-50 15 4 1 20 
50-60 19 4 2 25 
60-70 23 1 2 26 
70-80 14 1 0 15 
>80 1 0 0 1 
Total 75 10 5 90 
 
Fig 14 : Age Vs Outcome 
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Table 10 : Age * outcome Cross tabulation 
 
outcome 
Total 
improved status quo mortality 
age 
Below 
40 
Count 2 0 0 2 
Expected Count 1.7 .1 .2 2.0 
% within 
age_samples 100.0% .0% .0% 100.0% 
% within 
outcome_effect 2.7% .0% .0% 2.2% 
Age 
41-50 
Count 15 1 4 20 
Expected Count 16.7 1.1 2.2 20.0 
% within 
age_samples 75.0% 5.0% 20.0% 100.0% 
% within 
outcome_effect 20.0% 20.0% 40.0% 22.2% 
Age 
51-60 
Count 19 2 4 25 
Expected Count 20.8 1.4 2.8 25.0 
% within 
age_samples 76.0% 8.0% 16.0% 100.0% 
% within 
outcome_effect 25.3% 40.0% 40.0% 27.8% 
Age 
61-70 
Count 25 2 1 28 
Expected Count 23.3 1.6 3.1 28.0 
% within 
age_samples 89.3% 7.1% 3.6% 100.0% 
% within 
outcome_effect 33.3% 40.0% 10.0% 31.1% 
Age 
70 and 
above 
Count 14 0 1 15 
Expected Count 12.5 .8 1.7 15.0 
% within 
age_samples 93.3% .0% 6.7% 100.0% 
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% within 
outcome_effect 18.7% .0% 10.0% 16.7% 
Total 
Count 75 5 10 90 
Expected Count 75.0 5.0 10.0 90.0 
% within 
age_samples 83.3% 5.6% 11.1% 100.0% 
% within 
outcome_effect 100.0% 100.0% 100.0% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
 Pearson Chi-Square 5.927a 8 .655 
 Likelihood Ratio 7.272 8 .508 
 Linear-by-Linear  
 Association 2.473 1 .116 
a. 11 cells (73.3%) have expected count less than 5. The minimum 
expected count is .11. 
 
No Significant association is exist between Age and outcome.  
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Age and ventilator use: 
The number of patients put on ventilator in the age groups 40-50, 
50-60, 60-70 is 7, 6, 1 respectively. In the study group, the use of 
ventilator increases as the age advances. None of  patients less than 40 
years or above 70 years were put on ventilator. The use of ventilator is 
more with older patients.  This relationship is statistically significant at 
p=0.020. 
 
 
Fig 15 : Age with use of ventilator 
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Table 11 : Age Vs use of Ventilator 
Age  Yes No Total P-value 
≤40 0 3 3 
.020(S) 
40-50 7 13 20 
50-60 6 19 25 
60-70 1 25 26 
70-80 0 15 15 
>80 0 1 1 
Total 14 76 90 
 
By chi-square test, there is a significant association between the 
age and the use of ventilator,P≤0.05(P=0.020).  
Age and hospital stay: 
In the study population  the average number of hospital stay is 7 
days. It is seen that as age advances the duration of hospital stay increases 
with older people having the need to stay longer. This association is 
statistically significant at p=0.055 (by ANOVA). 
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Table 12 : Age Vs Hospital Stay 
Age <5days 5 -10 days 10-15days >15 days Total 
P-
value 
≤40 0 3 0 0 3 
.055(S) 
40-50 3 9 7 1 20 
50-60 9 8 6 2 25 
60-70 13 7 6 0 26 
70-80 6 6 3 0 15 
>80 1 0 0 0 1 
Total 32 33 22 3 90 
 
 
Influence of gender on outcome: 
The mortality among female patients in the study is 2 out of 9 
(18%). The moratlity among the male patients is 8 out of 68 
(11.8%).There is no significant association between gender and outcome. 
This could be attributed to the very low number of  female participants in 
the study. 
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Table 13 : Gender Vs Outcome 
 
outcome 
Total Improved Mortality Status Quo 
Male 68 8.0 5.0 81.0 
Female 7 2.0 0.0 9.0 
Total 75.0 10.0 5.0 90. 
 
Tabel 14 : Gender Vs outcome Crosstab 
 sex 
Total 
 Male Female 
out 
come_ 
effect 
Improved 
Count 68 7 75 
Expected Count 67.5 7.5 75.0 
% within outcome_effect 90.7% 9.3% 100.0% 
% within sex 84.0% 77.8% 83.3% 
status_ 
quo 
Count 5 0 5 
Expected Count 4.5 .5 5.0 
% within outcome_effect 100.0% .0% 100.0% 
% within sex 6.2% .0% 5.6% 
Mortality 
Count 8 2 10 
Expected Count 9.0 1.0 10.0 
% within outcome_effect 80.0% 20.0% 100.0% 
% within sex 9.9% 22.2% 11.1% 
Total 
Count 81 9 90 
Expected Count 81.0 9.0 90.0 
% within outcome_effect 90.0% 10.0% 100.0% 
% within sex 100.0% 100.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
  Pearson Chi-Square 1.704a 2 .427 
  Likelihood Ratio 1.979 2 .372 
  Linear-by-Linear     
  Association .650 1 .420 
  N of Valid Cases 90   
a. 3 cells (50.0%) have expected count less than 5. The minimum 
expected count is .50. 
 
There is no association between gender and outcome. 
 
Impact of gender on duration of hospital stay and use of ventilator: 
Male patients had longer in-hospital stay compared to female 
patients. This association is statistically significant at p=0.009. However 
there is no gender difference in the use of ventilator. 
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Table 15 : Gender and Hospital stay 
Gender 
Hospital stay 
Total 
P-
value 
<5days 
5 to 10 
days 
10 to 
15 
days 
>15days 
 
 Male 28.8 28.8 20.7 2.7 81.0  
Female 3.2 3.2 2.3 .3 9.0 .009(S) 
Total 32.0 32.0 23.0 3.0 90.0  
By chi-square test, there is a significant association between the gender 
and hospital stay. P≤0.05(P=0.009). 
 
Impact of gender on use of ventilator 
12 out of 69 (17.4%)  male patients were put  ventilator whereas  2 
out of 9 (22.2%)  female patients were ventilated.  There is no statistically 
significant  gender difference in the need of ventilator use among the 
study population.  
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Table 16: Gender and use of ventilator 
Gender 
Use of ventilator 
Total P-value 
Yes No 
 Male 12 69 81.0  
Female 2 7 9.0 0.561(NS) 
Total 14.0 76.0 90.0  
By chi-square tests, there is no significant association between the 
gender and use of ventilator, P≥0.05(P=0.561). 
Impact of corpulmonale on outcome: 
The mortality among patients with corpulmonale is 27.3 % ( 6/22). 
The mortality among patients without corpulmonale is 5.9% (4/68). 
Among  the study population, patients having corpulmonale and 
pulmonary hypertension had higher mortality. Most of the patients who 
did not  have PHT  improved. This association between corpulmonale and 
outcome is statistically significant at p=0.015. 
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Corpulmonale 
              Outcome 
Total P-value 
Improved Mortality Status Quo 
Mild PHT 
Moderate PHT 
Severe PHT 
No PHT 
5 2 2 9.0  
1 1 0 2.0 0.015(S) 
7 3 1 11.0  
62 4 2 68.0  
Total 75.0 10.0 5.0 90.0  
 
Fig 16 : Corpulmonale and outcome 
By chi-square tests, there is a significant association between Cor 
pulmonale and outcome, P≤0.05, (P=.015). 
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Impact of corpulmonale on ventilator usage: 
9 out of 22 (41%) patients with corpulmonale required ventilator 
support. 5 out of 63 (8%) persons without corpulmonale required 
ventilator support. There was increased need for usage of ventilators in  
patients with pulmonary hypertension compared to patients without PHT. 
This relationship was statistically significant at p<0.05. Most of the 
patients without  PHT didn’t require ventilator. 
 
Corpulmonale 
Use of ventilator 
Total P-value 
Yes No 
   Mild PHT 
   Moderate PHT 
   Severe PHT 
   No PHT 
  
1 8 9.0  
1 1 2.0 0.000(S) 
7 4 11.0  
5 63 68.0       
Total 14.0 76.0 90.0  
Fig 17 : Corpulmonale and use of ventilator 
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By chi-square test, there is a significant association between the 
Corpulomonale and use of ventilator, P=0.000.  
Impact of corpulmonale on duration of in-hospital stay: 
Patients with corpulmonale had a longer duration of hospitay stay. 
Patients without corpulmonale stayed for only 5-10 days. This relation 
was statistically significant at p =0.03. 
Table 17 : Corpulmonale and hospital stay 
Corpulmonale 
Hospital stay 
Total P-value 
<5days 
5 to 
10days 
10 to 15 
days 
>15day
s 
 Mild PHT 3.2 3.2 2.3 .3 9.0  
Moderate PHT .7 .7 .5 .1 2.0 .003(NS
) 
Severe PHT 3.9 3.9 2.8 .4 11.0  
No PHT 24.2 24.2 17.4 2.3 68.0  
Total 32.0 32.0 23.0 3.0 90.0  
By chi-square test, there is a significant association between the 
Corpulmonale and hospital stay, P≤0.05, (P=.003). 
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Impact of grade of dyspnea on outcome: 
In  patients getting admitted with AECOPD, as the eMRC dysnea 
grade increases, the mortality increases. Almost all the patients in the 
score of 4 and 5a got  improved.  Mortality is predominantly seen in 
eMRC 5b group.  The mortality rate among eMRC 5b is 10 out of 
35(28.6%).  The relation is statistically significant at p=0.000. 
 
Fig  18 : Dyspnea Score Vs outcome 
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Table 18 : Dyspnea Score Vs outcome 
 
Dysnea Score Vs 
Outcome Improved Moratlity 
Status 
Quo Total 
4 33 0 0 33 
5a 21 0 1 22 
5b 21 10 4 35 
Total 75 10 5 90 
 
Chi-Square Tests 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 23.536a 4 .000 
Likelihood Ratio 28.198 4 .000 
Linear-by-Linear 
Association 18.916 1 .000 
N of Valid Cases 90   
 
a. 6 cells (66.7%) have expected count less than 5. The minimum 
expected count is 1.22. 
 
Significant association exists between dyspnea  and outcome at p=0.000 
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Impact of dyspnea on duration of hospital stay: 
With increasing grade of dyspnea, the in-hospital stay for patients 
admitted with AECOPD increases . This association is statistically 
significant.  By chi-square test, the association between the dysnea score 
and hospital stay is P=0.000 (P≤0.05). 
Table 19 : Dyspnea score and hospital stay 
Dysnea Score Vs 
Hospital Stay 
Hospital stay 
Total P-value 
<5days 5 to10days 
10 to 15 
days >15days 
 4 24 8 1 0 33.0  
5a 4 11 7 0 22.0 0.000(S) 
5b 4 13 15 3 35.0  
Total 32.0 32.0 23.0 3.0 90.0  
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Impact of dyspnea on ventilator use: 
With increasing grade of dyspnea there is increased usage of  
ventilator. None of the patients in the score of 4 and 5a required ventilator 
whereas 66% in the dyspnea score of 5b required ventilator. This 
association is statistically significant at p=0.000. 
 
Dyspnea Score Vs Use of ventilator Yes No Total P-value 
4 0 33 33 
0.000(S) 
5a 0 22 22 
5b 14 21 35 
Total 14 76 90 
Fig 19 : Dyspnea and ventilator use 
 By chi-square test, there is a significant association between the dyspnea 
score and use of ventilator, P≤0.05,(P=0.000).  
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Impact of Eosinopenia on outcome: 
All the 6 patients with eosinopenia improved. None of the patients 
with  eosinopenia died during hospital stay. There is no significant 
association between eosinopenia and outcome. 
 
Table 20 :  Crosstab Eosinopenia and outcome 
 
Eosinopenia 
Total yes No 
outcome improved 6 69 75 
status quo 0 5 5 
mortality 0 10 10 
Total 6 84 90 
 
Chi-Square Tests 
 Value Df 
Asymp. Sig. (2-
sided) 
  Pearson Chi-Square 1.286a 2 .526 
  Likelihood Ratio 2.272 2 .321 
  Linear-by-Linear     
  Association 1.160 1 .281 
   N of Valid Cases 90   
a. 3 cells (50.0%) have expected count less than 5. The minimum 
expected count is .33. 
 
No significant association between eosinopenia and outcome 
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Impact of Consolidation on Outcome: 
 
9 out of the 10 (90%) patients in the mortality group had chest X-
ray features of consolidation. Out of 75 patients  who improved 16 
(21.3%) had consolidation. Presence of consolidation is associated with 
higher mortality. This association is statistically significant at p=0.000 
 
Table 21 : Crosstab consolidation and outcome 
 
 
consolidation 
Total Yes No 
Outcome improved 16 59 75 
status_quo 4 1 5 
mortality 9 1 10 
Total 29 61 90 
 
Chi-Square Tests 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 24.583a 2 .000 
Likelihood Ratio 23.879 2 .000 
Linear-by-Linear 
Association 23.136 1 .000 
N of Valid Cases 90   
a. 3 cells (50.0%) have expected count less than 5. The minimum 
expected count is 1.61. 
 
Significant association exists between consolidation and outcome. 
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Impact of acidemia on outcome: 
 
All 10 (100%) patients with in-hospital mortality had arterial blood 
pH<7.30. 14 out of 75(18.7%)  patients who improved had acidemia. 
Presence of acidemia is associated with higher in-hospital mortality. This 
relation is statistically significant at p=0.00 
Table 22 : Crosstab acidemia and outcome 
 
 
 
Acidemia 
Total yes no 
Outcome Improved 14 61 75 
status quo 1 4 5 
Mortality 10 0 10 
Total 25 65 90 
 
Chi-Square Tests 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 29.254a 2 .000 
Likelihood Ratio 29.145 2 .000 
Linear-by-Linear 
Association 25.589 1 .000 
N of Valid Cases 90   
 
a. 3 cells (50.0%) have expected count less than 5. The minimum 
expected count is 1.39. 
 
Significant association  exists between acidemia and outcome. 
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Impact of atrial fibrillation on outcome: 
 
 
In the study group 2 patients had atrial fibrillation. Both the 
patients died during the course of treatment. In terms of percentage, 20% 
of the patients with in-hospital mortality had atrial fibrillation.  Presence 
of atrial fibrillation is associated with higher mortality. By Chi square this 
relation is statistically significant at p=0.03. 
 
Table 23 : Crosstab atrial fibrillation and outcome 
 
 
  
 
Fibrillation 
Total yes no 
Outcome improved 2 73 75 
Status quo 0 5 5 
mortality 2 8 10 
Total 4 86 90 
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Chi-Square Tests 
 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 6.488a 2 .039 
Likelihood Ratio 4.276 2 .118 
Linear-by-Linear 
Association 5.106 1 .024 
N of Valid Cases 90   
 
a. 4 cells (66.7%) have expected count less than 5. The minimum 
expected count is .22. 
 
Significant association exists between atrial fibrillation and outcome. 
The DECAF score and outcome: 
 
The DECAF score comprising the five variables – Dyspnea, 
Eosinopenia, Consolidation, Acidemia, atrial Fibrillation is strongly 
associated with outcome. There is no mortality in the in patients with 
DECAF score between 0-2. The mortality rate for patients getting score 
of 3 and above is 10 out of 31. In terms of percentage this is 32.3%.  The 
higher is the DECAF score , the higher is the  mortality. This relation is 
statistically significant at p=0.000. 
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DECAF Score Vs 
Outcome Improved Moratlity 
Status 
Quo Total 
0 - 1(Low risk) 44 0 0 44 
2 (Intermediate risk) 14 0 1 15 
3-6 (High risk) 17 10 4 31 
Total 75 10 5 90 
 
Fig 20 : DECAF score and outcome 
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Table 24 : Crosstab DECAF and outcome 
 
 DECAF 
Total 
 0 1 2 3 4 5 
outcome 
improved 
Count 31 13 14 10 6 1 75 
Expected 
Count 25.8 10.8 12.5 11.7 12.5 1.7 75.0 
% within 
outcome
_ 
effect 
41.3% 17.3% 18.7% 13.3% 8.0% 1.3% 100.0% 
% within 
DECAF 100.0% 100.0% 93.3% 71.4% 40.0% 50.0% 83.3% 
status_ 
quo 
Count 0 0 1 4 0 0 5 
Expected 
Count 1.7 .7 .8 .8 .8 .1 5.0 
% within 
outcome
_ 
effect 
.0% .0% 20.0% 80.0% .0% .0% 100.0% 
% within 
DECAF .0% .0% 6.7% 28.6% .0% .0% 5.6% 
mortality 
Count 0 0 0 0 9 1 10 
Expected 
Count 3.4 1.4 1.7 1.6 1.7 .2 10.0 
% within 
outcome
_ 
effect 
.0% .0% .0% .0% 90.0% 10.0% 100.0% 
% within 
DECAF .0% .0% .0% .0% 60.0% 50.0% 11.1% 
Total 
Count 31 13 15 14 15 2 90 
Expected 
Count 31.0 13.0 15.0 14.0 15.0 2.0 90.0 
% within 
outcome
_ 
effect 
34.4% 14.4% 16.7% 15.6% 16.7% 2.2% 100.0% 
% within 
DECAF 100.0% 100.0% 100.0% 
100.0
% 100.0% 
100.0
% 100.0% 
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Chi-Square Tests 
 
 Value DF Asymp. Sig. (2-sided) 
  Pearson Chi-Square 65.403a 10 .000 
  Likelihood Ratio 53.134 10 .000 
  Linear-by-Linear  
  Association 29.522 1 .000 
  N of Valid Cases 90   
 
a. 13 cells (72.2%) have expected count less than 5. The minimum 
expected count is .11. 
Significant association exists between DECAF score and outcome  
 
DECAF score and use of ventilator: 
As the DECAF score increases the need for ventilator use  
increases. In the low and intermediate risk group (DECAF 0-2)   only one 
patient was ventilated. In the high risk group 13 out of 31 persons were 
ventilated.  In terms of percentage this is 1.7% and 41%  in the low-
intermediate risk group and high risk group respectively.  This 
association is statistically significant at p=0.000.  
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DECAF Score Vs Use of Ventilator Yes No Total P-value 
0 – 1 (Low risk) 0 44 44 
0.000(S) 
2 (Intermediate risk) 1 14 15 
3-6 (High risk) 13 18 31 
Total 14 76 90 
Fig 21 : DECAF score and use of ventilator 
By chi-square test, there is a significant association between the DECAF  
score and outcome,P≤0.05,(P=0.000).  
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DECAF score and duration of hospital stay:  
The average duration of hospital stay for the low to  intermediate 
risk group (DECAF 0-2) was 6.1. Whereas the average duration of 
hospital stay for the high risk group (DECAF 3-6) is 9.3.  The higher is 
the DECAF score, the longer is the hospital stay. This association 
between the DECAF score and in-hospital stay is statistically significant 
at p=0.01. 
 
Table 25 : Cross tabulation DECAF Score and Hospital stay 
 
Count 
 DECAF 
Total  0 1 2 3 4 5 
Association 
between 
DECAF 
Score and 
Hospital 
stay 
upto 3 days 6 1 0 0 2 0 9 
upto 6 days 23 8 5 4 3 0 43 
upto 9 days 1 2 3 4 2 0 12 
upto12 days 0 1 3 4 3 1 12 
upto 15 days 1 1 3 2 3 1 11 
upto 18 days 0 0 1 0 2 0 3 
Total 31 13 15 14 15 2 90 
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Chi-Square Tests 
 Value df Asymp. Sig.  (2-sided) 
  Pearson Chi-Square 44.865a 25 .009 
  Likelihood Ratio 51.370 25 .001 
  Linear-by-Linear  
  Association 23.808 1 .000 
  N of Valid Cases 90   
 
a. 31 cells (86.1%) have expected count less than 5. The minimum 
expected count is .07. 
Chi-square value 44.87 for DF 25 was found to be statistically 
significant at 0.01 and 0.05 level. From the results it was observed that 
significant association exists between the DECAF score and Hospital 
stay. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 22: DECAF score and hospital stay 
AGE and DECAF score: 
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The number of patients less than 60 years of age in the low, 
intermediate and high risk groups are 18, 12 and 18 respectively. The 
number of patients more than 60 years of age in the low, intermediate and 
high risk groups are 26, 3 and 13 respectively. The age distribution of 
low, intermediate and high risk groups is shown in the table. There is no 
significant relation between age and DECAF score. 
 
Table 26 : Age and DECAF score 
 
Age DECAF score Total  P-value 
 Low risk 
(0-1) 
Intermediate 
risk (2) 
High 
risk (3-
6) 
  
<=40 0 2 1 3  
40-50 8 4 8 20 0.209(NS) 
50-60 10 6 9 25  
60-70 15 3 8 26  
70-80 10 0 5 15  
>80 1 0 0 1  
Total 44 15 31 90  
 
Gender and DECAF score: 
The number of female   patients in low, intermediate and  high risk 
groups are 4,2 and 3 respectively. In terms of percentage this is 44, 22.2 
and 33.3 respectively. The number of male  patients in low, intermediate 
and  high risk groups are 40, 13 and 28 respectively.  In terms of 
percentage this is 49.4, 16 and 34.6 respectively. There was no 
significant association between DECAF score and gender. 
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Table 27 :  Gender and DECAF score 
Gender DECAF score Total P-value 
 Low risk 
(0-1) 
Intermediate 
risk (2) 
High 
risk (3-6) 
  
Female 4 2 3 9  
Male 40 13 28 81 0.892(NS) 
Total 44 15 31 90  
 
Dyspnea grade and DECAF score: 
In patients with dyspnea grade 4 all 33 patients were in low risk 
group. In patients with  dyspnea grade 5a the number of patients in low, 
intermediate and  high risk groups are 10,9 and 3 respectively. In terms of 
percentage this is 45.5, 41 and 13.6 respectively.  In patients with  
dyspnea grade 5b the number of patients in low, intermediate and  high 
risk groups are 1,6 and 28 respectively. In terms of percentage this is 2.9, 
17.1 and 80 respectively.  Patients with higher grade of dyspnea 
according to eMRC had higher DECAF score. Patients  having a dyspnea 
grade of 4 and 5a had better prognosis than patients having a grade 5b. 
This association is statistically significant p=0.000. 
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Dyspnea Score Vs DECAF Score 
DECAF  Score 
Total 
P-value 
0-1 2 3-6 
0.000(S) 
4 33 0 0 33 
5a 10 9 3 22 
5b 1 6 28 35 
Total 44 15 31 90 
 
Fig 23 :  Dyspnea score and DECAF score 
By chi-square test, there is a significant association between the Dysnea 
Score and Decaf score, P≤0.05, (P= 0.000). 
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Corpulmonale and DECAF score: 
 In patients with  corpulmonale  the number of patients in low, 
intermediate and  high risk groups are 4,2 and 16  respectively. In terms 
of percentage this is 18.2, 9.1 and 72.7 respectively.   In patients without  
corpulmonale  the number of patients in low, intermediate and  high risk 
groups are 40, 13 and 15  respectively. In terms of percentage this is 58.8, 
19.1 and 22.1 respectively. Patients with corpulmonale had higher 
DECAF score. Most of the patients without  pulmonary hypertension had 
a score of 0 to 2 with good prognosis. This association between DECAF 
score and corpulmonale is statistically significant at p=0.03. 
Table 28 : Corpulmonale and DECAF score 
Cor 
pulmonale 
DECAF score Total P-value 
 Low 
risk  
(0-1) 
Intermediate 
risk (2) 
High 
risk  
(3-6) 
  
Mild PHT 3 2 4 9  
Moderate PHT 0 0 2 2 0.000(S) 
Severe PHT 1 0 10 11  
No PHT 40 13 15 68  
Total  44 15 31 90  
By chi-square tests, there is a significant association between the 
Corpulmonale and DECAF score.  
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Use of ventilator and mortality: 
The mortality rate among patients who were ventilated and those 
not ventilated are 57.1% and 2.6% respectively. There was higher 
mortality among patients who were ventilated. This relation between use 
of ventilator and outcome is statistically significant at p=0.000. 
 
 
Use of 
ventilator Outcome Total 
 Improved Mortality Status quo  
Yes 5 8 1 14 
No 70 2 4 76 
Total 75 10 5 90 
 
Fig 24 : Use of ventilator and outcome 
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Table 29 : Crosstab – use of ventilator and outcome 
   Ventilator 
Total 
   yes No 
outcome 
Improved 
Count 5 70 75 
 Expected Count 11.7 63.3 75.0 
 % within  
 outcome_effect 6.7% 93.3% 100.0% 
 % within 
ventilation 35.7% 92.1% 83.3% 
status quo 
 Count 1 4 5 
 Expected Count .8 4.2 5.0 
 % within   
 outcome_effect 20.0% 80.0% 100.0% 
 % within 
ventilation 7.1% 5.3% 5.6% 
Mortality 
 Count 8 2 10 
 Expected Count 1.6 8.4 10.0 
 % within   
 outcome_effect 80.0% 20.0% 100.0% 
 % within 
ventilation 57.1% 2.6% 11.1% 
Total 
 Count 14 76 90 
 Expected Count 14.0 76.0 90.0 
 % within  
 outcome_effect 15.6% 84.4% 100.0% 
 % within 
ventilation 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
  Pearson Chi-Square 36.203a 2 .000 
  Likelihood Ratio 26.049 2 .000 
  Linear-by-Linear    
  Association 34.006 1 .000 
  N of Valid Cases 90   
 
a. 3 cells (50.0%) have expected count less than 5. The minimum 
expected count is .78 
Significant association is exist between outcome and use of ventilation 
 
 Hospital stay and outcome: 
 The average hospital stay for study population was 7. Longer in-
hospital stay was not associated  with better prognosis. There was no 
significant relationship between duration of hospital stay and outcome. 
Table 30 : Hospital stay and outcome 
Hospital 
stay 
Outcome Total P-value 
 Improved Mortality Status 
quo 
  
>5 days 30 1 1 32  
5-10 days 27 3 2 32 0.270(NS) 
10-15 days 16 5 2 23  
>=15 days 2 1 0 3  
Total  75 10 5 90  
By chi-square test, there is no significant association between hospital 
stay and outcome, P≥0.05,P=0.270. 
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Ventilator use and hospital stay : 
The average duration of hospital stay for patients  who were 
ventilated and not ventilated  is 11.1 and 6.5 respectively. Patients who 
were put on ventilator had longer hospital stay, compared to patients not 
ventilated. This association is statistically significant at p=0.001 
 
Table 31 : Use of ventilator and hospital stay 
Hospital Stay 
Use of Ventilator 
Total 
 
Yes No P-value 
  <5days 1 31 32.0  
5to 10 days 3 29 32.0 0.001(S) 
10 to 15 days 8 15 23.0  
>15 days 2 1 3.0  
Total 14.0 76.0 90.0  
By chi-square test, there is a significant association between hospital stay 
and use of ventilator, P≤0.05, P=0.001. 
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Prediction analysis on outcome based on the DECAF score and use of 
ventilator. 
 
 
Fig 25 : Normal P-P Plot of Regression Standardized Residual 
 
 
In predicting the outcome, the influence of DECAF and use of 
ventilation is a significant one . The R-Square value of 0.477 explains 47 
percent of total variance. It has been confirmed by the f-value of 26.17 
which was significant at 0.05 level and confirms that not occurred by a 
chance.   
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DISCUSSION 
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Clinical Profile of the study population: 
A total of 90 patients were included in our study as per our patient 
selection methods, inclusion and exclusion criteria.  The age group of our 
patients in our study ranged from 37 to 82. The number of patients in the 
age groups ≤40, 40-50, 50-60, 60-70, 70-80, >80 were 3 (3.3%), 20 
(22.2%), 25 (27.8 %), 26 (28.9%), 15(16.7%) and 1(1.1%) respectively. 
This distribution shows that we had more patients in older age groups 
than younger age groups. This is consistent with the fact that age is often 
listed as a risk factor for COPD49. It is unclear if healthy aging as such 
leads to COPD or if age reflects the sum of cumulative exposures 
throughout life.  Beyond 70 years of age there are fewer study subjects. 
This situation may have arisen because of  exclusion of patients with 
other co-morbidities. Since co-morbid illnesses are common with aged 
population we had this sort of age distribution of patients. 
Out of the 90  patients in the study, 81 are male and 9 are female. 
Thus males accounted for 90% of our study population while females 
accounted for 10%. This could be attributed to low prevalence of 
smoking among ladies. This shows that smoking habit may not have 
entered into our female population as much as in the western literature.  
Another reason could be that many female patients with COPD are 
usually branded as having asthma in our country. The primary reason for 
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females developing COPD in our country could be attributed to passive 
smoking, biomass exposure and post tuberculosis.  
In the study population, 47 did not have any comorbid illness.  The 
most common comorbidity among the study population was Pulmonary 
Tuberculosis Sequalae. 22 patients had history and radiological features 
of prior pulmonary tuberculosis.  6 patients had systemic hypertension, 2 
patients had chronic kidney disease, 1 patient had both hypertension and 
diabetes mellitus,  4  patients had coronary artery disease, 2 patients had 
obstructive sleep apnea, 3 patients had connective tissue disorders, 3 
patients had hypersensitivity pneumonitis.  This is consistent with the 
finding that tuberculosis has been found to be risk factor for COPD1. In 
addition tuberculosis is a potential comorbidity in COPD patients. Severe 
respiratory infections have been associated with reduced lung function.  
Three patients in the study had coexistent hypersensitivity pneumonitis. 
Estimates by American Thoracic Society concluded that occupational 
exposures account for 10-20% of either symptoms  or functional 
impairment consistent with COPD50. The risk from occupational 
exposures in less regulated areas like India is likely to be much higher 
than reported in Western literature. 
Corpulmonale is classically defined as “hypertrophy of the right 
ventricle resulting from diseases affecting the function and/or structure of 
the lungs except when these pulmonary alterations are the result of 
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diseases that primarily affect the left side of the heart”51. Out of 90 
patients included in the study 22 (24.4%)  patients had corpulmonale as 
evidenced on echo. Out of them 9 (10%) patients had mild pulmonary 
hypertension (PHT), 2 (2.2%) patients had moderate PHT, 11 (12.2%)  
patients had severe PHT.  This is consistent with other studies that have 
reported prevalence varying considerably from 20%–91%52,53  depending 
on the definition of pulmonary hypertension, the severity of lung disease 
in the group studied and the method of measuring the pulmonary artery 
pressure (PAP). During an exacerbation of COPD, PAP may rise by as 
much as 20 mm Hg and return to its baseline after recovery53. Pulmonary 
hypertension in COPD has been considered to be the result of hypoxic 
pulmonary vasoconstriction, polycythemia and destruction of the 
pulmonary vascular bed by emphysema. Recently, it has been recognized 
that hyperinflation and endothelial dysfunction also play a role in the 
pathogenesis of PH. 
MRC dyspnea scale is used for dyspnea grading because it is 
simple and allows patients to indicate the level of breathlessness.  
Extended Medical Research Council (eMRC) is used since it includes 
functional dependence as well. When dyspnea was graded according to  
eMRC grades,  33 patients had eMRC grade 4, 22 patients had eMRC 
grade 5a and 35 patients had a score of 5b. In terms of percentage, the 
distribution of patients in grades 4, 5a and 5b was  36.7, 24.4 and 38.9 
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respectively. Since patients were admitted with acute exacerbation of 
COPD most of them had dyspnea at rest, grade 5 which was again 
subdivided into 5a and 5b based on functional dependence. The patients 
with grade 4 dyspnea, though they did not have  dyspnea at rest, they 
were admitted for AECOPD with increased quantity and purulency of 
sputum. 
Eosinopenia was defined as an absolute eosinophil count of less 
than 50/mm3. 6 out of 90 patients had eosinopenia. Hence 6.7% of the 
study population had low eosinophil count. The incidence of eosinopenia 
is comparatively lower in our study population compared to western 
literature.  It has been shown in previous studies that eosinopenia 
accompanies the response to acute infection and inflammation22. Thus in 
AECOPD eosinopenia may reflect severity of accompanying acute 
inflammatory response. 
Assessment of chest radiographs of patients at admission to 
confirm the presence of consolidation was done. Accordingly 25 
(27.77%) patients had consolidation on chest radiograph. Similar  
prevalence of 32.5% of consolidation in patients with AECOPD was 
reported by J Steer et al19 in his study of 920 patients.  In two  UK  
national audits26,27, consolidation was reported in 16% of all  admissions 
and in 34% of patients requiring  ventilator assistance. Many a times the 
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cause for an acute exacerbation of COPD is infectious and related to viral 
or bacterial infection. 
Out of 90 patients 25 patients (27.77%) had acidemia. This is 
consistent with various studies that have reported a prevalence between 
25% to 53%19,21. In a study  involving consecutive patients admitted with 
AECOPD over one and half year period in UK, the  incidence of 
acidemia was 27.9%.  
Respiratory acidosis in COPD is secondary to hypoventilation. It 
includes multiple mechanisms including decreased responsiveness to 
hypoxia and hypercapnia, increased ventilation-perfusion mismatch 
leading to increased dead space ventilation and decreased diaphragmatic 
function due to fatigue and hyperinflation.  
Among the study population 4 (4.4%)  patients had atrial 
fibrillation, while the remaining 86 did not have fibrillation. This 
incidence is lower compared to other studies which have reported an  
occurrence of above 12%39. Acidemia, drugs and corpulmonale 
contribute to occurrence of arrythmias  in COPD patients. It is postulated 
that ectopic beats initiating atrial fibrillation originate in the walls of 
pulmonary veins and it could be triggered by changes in gas 
composition38. 
The average duration of hospital stay for the study group was 7 
days.  The length of hospital stay was divided into four groups- <5 days, 
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5-10 days, 10-15 days, >15 days.  32 patients had hospital stay lesser than 
5 days, 32 patients had hospital stay between 5-10 days, 23 patients  had 
hospital stay between 10-15 days, 3 patients stayed in hospital longer than 
15 days.  In the study by Ying et al54 in Oslo involving 590 patients 
admitted with AECOPD, the median length of hospital was 6 days. 
Various studies have illustrated wide range of hospital stay  between 3-11 
days.  
The mortality rate for the study population was 10 out of 90 (11%). 
75 patients “improved” at the time of discharge, 10 patients died in the 
hospital, 5 patients were discharged against medical advice whose clinical 
condition could not be defined as ‘improved’ or deteriorated at the time 
of leaving the hospital.  This study confirms the findings of previous 
studies. Karin H Groenewegen  et al33, in a study of  171 patients 
admitted with AECOPD showed the  mortality rate during hospital stay 
was 8%, increasing to 23% after 1 year of follow-up. In the study by  
J Steer et al19 the in-hospital mortality rate was 10.4% (96/920) . In the 
study by Connors et al55 the in-hospital mortality was 11%.  
Out of the 90 patients  14(15.6%) were put on ventilator, 6 were 
put on non invasive ventilation and 8 were put on Invasive ventilation. 
This is consistent  with the previous studies that have reported ventilator 
use between 8 to 12% in patients getting admitted with AECOPD32,33. 
Factors influencing in-hospital prognosis: 
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The mortality in the age groups 40-50, 50-60, 60-70, 70-80 is 
4,4,1,1 respectively.  When age was taken as scattered variables, older 
patients showed higher mortality. However there is no statistically 
significant association between age and outcome,P≥0.05(P=0.800).  The 
number of patients put on ventilator in the age groups 40-50, 50-60, 60-
70 is 7, 6, 1 respectively. In the study group, the use of ventilator 
increases as the age advances. None of the patients less than 40 years or 
above 70 years were put on ventilator. The use of ventilator is more with 
older patients.  This  relationship is statistically significant at p=0.020. In 
the study population  the average number of hospital stay is 7 days. It is 
seen that as age advances the duration of hospital stay increases with 
older people having the need to stay longer. This association is 
statistically significant at p=0.055 (by ANOVA). These findings show 
that younger patients have milder forms of the disease compared to older 
patients. This could be attributed to decline in lung function as age 
advances and presence of comorbid illness which are more in older 
patients. 
The mortality among female patients in the study is 2 out of 9 
(18% ). The mortality among the male patients is 8 out of 68 
(11.8%).There is no significant association between gender and outcome. 
This could be attributed to the very low number of  female participants in 
the study. Male patients had longer in-hospital stay compared to female 
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patients. This association is statistically significant at p=0.009. 12 out of 
69 (17.4%)  male patients were put  on ventilator whereas  2 out of 9 
(22.2%)  female patients were ventilated.  There is no statistically 
significant  gender difference in the use of ventilator among the study 
population. This agrees with the findings by S Yu et al56 and Cooper et 
al57 who showed that gender was not an independent risk factor for short 
or long term prognosis in acute exacerbation of COPD. 
The mortality among patients with corpulmonale is 27.3 % (6/22). 
The mortality among patients without corpulmonale is 5.9% (4/68). 
Among  the study population, patients having corpulmonale and 
pulmonary hypertension had higher mortality. Most of the patients who 
did not  have PHT  improved. This association between corpulmonale and 
outcome is statistically significant at p=0.015. 9 out of 22 (41%) patients 
with corpulmonale required ventilator support. 5 out of 63 (8%) persons 
without corpulmonale required ventilator support. There was increased 
need for usage of ventilators in  patients with pulmonary hypertension 
compared to patients without PHT. This relationship was statistically 
significant at p<0.05. Most of the patients without  PHT didn’t require 
ventilator. Patients with corpulmonale had a longer duration of hospital 
stay. Patients without corpulmonale stayed for only 5-10 days. This 
relation was statistically significant at p=0.03. This finding agrees with 
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various studies by JJ Soler et al58, M Oswald et al59 which have showed 
that corpulmonale is an adverse prognostic variable in AECOPD. 
In  patients getting admitted with AECOPD, as the eMRC dyspnea 
grade increases, the mortality increases. Almost all the patients in the 
score of 4 and 5a got  improved.  Mortality is predominantly seen in 
eMRC 5b group.  The mortality rate among eMRC 5b is 10 out of 
35(28.6%).  The relation is statistically significant at p=0.000. With 
increasing grade of dyspnea there is increased usage of  ventilator 
support. None of the  patients in the score of 4 and 5a  required ventilator  
whereas 66% in the dyspnea score group of 5b required ventilator. This 
association is statistically significant at p=0.000. With increasing grade of 
dyspnea, the in-hospital stay for patients admitted with AECOPD 
increases . This association is statistically significant at p=0.000. In the 
study by E Steer et al21  the in hospital mortality rate for eMRCD 5b 
patients was 33.1%. The findings of the present study are consistent with 
previous studies1921 which  have showed that severity of dyspnea is 
strongly associated with both in-hospital mortality and early readmission. 
By combining MRCD scale with a person’s ability to manage personal 
care (eMRCD) the predictive value of dyspnea scoring is improved. 
All the 6 patients with eosinopenia improved. None of the patients 
with  eosinopenia died during hospital stay. In our study there is no 
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significant association between eosinopenia and outcome. The finding of 
our study is not comparable with other studies by Holland et al25 and  
J steer et al19 that have showed eosinopenia to be a significant prognostic 
factor in AECOPD. 
9 out of the 10 (90%) patients in the mortality group had chest X-
ray features of consolidation. Out of 75 patients  who improved 16 
(21.3%) had consolidation. Presence of consolidation is associated with 
higher mortality. This association is statistically significant at p=0.000. 
This is comparable to previous studies by Liebermann et al, J Steer et al 
who have shown that mortality among pneumonia associated AECOPD is 
more than non pneumonic AECOPD. Community acquired pneumonia is 
common among patients hospitalised with AECOPD and usually causes 
the exacerbation to have more severe clinical and laboratory parameters. 
All 10 (100%) patients with in-hospital mortality had arterial blood 
pH<7.30. 14 out of 75(18.7%)  patients who improved had acidemia. 
Presence of acidemia is associated with higher in-hospital mortality. This 
relation is statistically significant at p=0.00. According to previous 
studies56, the frequency of hypercapnic respiratory failure in patients with 
AECOPD varies from 16-35% with overall mortality of  
35-43%5. Our study has shown higher mortality among hypercapnic 
patients compared to previous studies. The level of hypercapnia, 
suggestive of chronic alveolar hypoventilation, reflects the severity of the 
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underlying respiratory condition, and Patients with chronic hypercapnia, 
who comprised the majority of our study population, have a worse 
prognosis than patients with normoventilation.  
In the study group 4 patients had atrial fibrillation. All of them died 
during the course of treatment. In terms of percentage, 20% of the 
patients with in-hospital mortality had atrial fibrillation.  Presence of 
atrial fibrillation is associated with higher mortality. By Chi square this 
relation is statistically significant at p=0.03. This is in accordance with 
study by J Steer et al19 in which 26% of patients with in hospital mortality 
had atrial fibrillation. Previous studies have shown that occurrence of 
atrial fibrillation is associated with poor prognosis.                                                                            
The average hospital stay for study population was 7. Longer in-
hospital stay was not associated with better prognosis. There was no 
significant relationship between duration of hospital stay and outcome.    
There are no clinical trials that have evaluated the optimal  duration of 
treatment in AECOPD. Our  study shows that prolonged hospital stay is 
not necessarily associated with improved outcome. 
The mortality rate among patients who were ventilated and those 
not ventilated are 57.1% and 2.6% respectively. There was higher 
mortality among patients who were ventilated. This relation between use 
of ventilator and outcome is statistically significant at p=0.000. The 
average duration of hospital stay for patients  who were ventilated and not 
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ventilated  is 11.1 and 6.5 respectively. Patients who were put on 
ventilator had longer hospital stay, compared to patients not ventilated. 
This association is statistically significant at p=0.001. Out of 14 patients 
who required ventilatory support, 8 were put on invasive ventilation and 6 
were put on non invasive ventilation. Use of ventilator improves acute 
respiratory acidosis, decreases respiratory rate, work of breathing, 
severity of breathlessness. However the higher incidence of mortality and 
longer hospital stay in patients put on ventilator may be attributed to the 
fact that weaning or discontinuation from mechanical ventilation can be 
difficult and hazardous in patients with COPD1.  In patients on ventilatory 
support there is higher incidence of ventilator associated pneumonia, 
barotraumas and need for longer antibiotic usage. This study highlights 
the need for trial of non invasive ventilation even in conditions where 
invasive ventilation is generally indicated. NIV can reduce the 
complications associated with intubation like ventilator associated 
pneumonia.  
The use of DECAF Score in assessing in-hospital prognosis: 
Out of 90 patients studied, 44 patients had a DECAF score between 
0-1 (low risk), 15 patients had a DECAF score of 2 (intermediate risk)  
and 31 patients had a DECAF score between 3-6(high risk). In terms of 
percentage this is 48.9%, 16.7% and 34.4% respectively. This is 
consistent with the study by J.Steer et al19 , in which the low risk group 
105 
 
comprised  53.5% of the study population, intermediate risk group 
comprised  24.5%of the study population, high risk group comprised 22% 
of the study population.  This shows that in a given population getting 
admitted with AECOPD, low risk group outnumber the high risk patients.  
This may be due to the fact that these patients approach health care 
facilities early during the course of exacerbation. The DECAF score 
comprising the five variables – Dyspnea, Eosinopenia, Consolidation, 
Acidemia, atrial Fibrillation is strongly associated with outcome. There is 
no mortality in the in patients with DECAF score between 0-2. The 
mortality rate for patients getting score of 3 and above is 10 out of 31. In 
terms of percentage this is 32.3%.  The higher is the DECAF score , the 
higher is the  mortality. This relation is statistically significant at 
p=0.000. Our study agrees with the findings by J Steer et al19. In their 
study  involving 920 AECOPD patients, the strongest five categorical 
variables strongly  associated with in-hospital mortality were selected and 
the DECAF score devised. They reported that in DECAF 0-1 the  in-
hospital mortality was 1.4%, in DECAF 2  mortality was 8.4%. and  in 
DECAF 3-6 the mortality was 34.6%. As the DECAF score increases use  
of ventilator increases. In the low and intermediate risk group (DECAF 0-
2)   1 out of 59 persons was ventilated. In the high risk group 13 out of 31 
persons were ventilated.  In terms of percentage this is 1.7% and 41%  in 
the low-intermediate risk group and high risk group respectively.   This 
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association is statistically significant at p=0.000.  The average duration of 
hospital stay for the low to  intermediate risk group (DECAF 0-2) was 
6.1. whereas the average duration of hospital stay for the high risk group 
(DECAF 3-6) is 9.3.   The higher is the DECAF score the longer is the 
hospital stay. This association between the DECAF score and in-hospital 
stay is statistically significant at p=0.01. To our knowledge there are no 
previous studies that have evaluated the association between DECAF 
score and need for ventilator use or duration of hospital stay. 
Factors related to DECAF score: 
The number of patients less than 60 years of age in the low, 
intermediate and high risk groups are 18, 12 and 18 respectively. The 
number of patients more than 60 years of age in the low, intermediate and 
high risk groups are 26, 3 and 13 respectively. There is no significant 
relation between age and DECAF score. The number of female   patients 
in low, intermediate and  high risk groups are 4,2 and 3 respectively. In 
terms of percentage this is 44, 22.2 and 33.3 respectively. The number of 
male  patients in low, intermediate and  high risk groups are 40, 13 and 
28 respectively.  In terms of percentage this is 49.4, 16 and 34.6 
respectively. There was no significant association between DECAF score 
and gender. 
In patients with dyspnea grade 4 all 33 patients were in low risk 
group. In patients with  dyspnea grade 5a the number of patients in low, 
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intermediate and  high risk groups are 10,9 and 3 respectively. In patients 
with  dyspnea grade 5b the number of patients in low, intermediate and  
high risk groups are 1,6 and 28 respectively. Patients  having a dyspnea 
grade of 4 and 5a had better prognosis than patients having a grade 5b. 
Patients with higher grade of dyspnea according to eMRC had higher 
DECAF score. This association is statistically significant p=0.000. In 
patients with  corpulmonale  the number of patients in low, intermediate 
and  high risk groups are 4,2 and 16  respectively. In terms of percentage 
this is 18.2, 9.1 and 72.7 respectively. In patients without  corpulmonale,  
the number of patients in low, intermediate and  high risk groups are 40, 
13 and 15  respectively. In terms of percentage this is 58.8, 19.1 and 22.1 
respectively. Patients with corpulmonale had higher DECAF score. Most 
of the patients without  pulmonary hypertension had a score of 0 to 2 with 
good prognosis. This association between DECAF score and  
corpulmonale is statistically significant at p=0.03. Hence higher dyspnea 
grade and presence of corpulmonale may be taken as indirect markers of 
higher DECAF score.  
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CONCLUSION 
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 The present study shows that in patients admitted with acute 
exacerbation of COPD the DECAF score comprising the five 
variables – Dyspnea, Eosinopenia, Consolidation, Acidemia, atrial 
Fibrillation is strongly associated with outcome.  
 Based on DECAF score these patients are divided into low risk  
(DECAF 0-1), intermediate risk (DECAF-2) and high risk 
(DECAF 3-6).  
 The higher  the DECAF score , the higher is the  mortality, the 
longer is the hospital stay and the higher is the need for use of 
ventilator.  
 Presence of corpulmonale can be considered as a surrogate marker 
of  higher DECAF score. 
 
The DECAF score is a simple clinical tool for assessing in-hospital 
prognosis in patients admitted with acute exacerbation of Chronic 
Obstructive Pulmonary Disease. This scoring system incorporates indices 
routinely available and can stratify patients admitted with AECOPD into 
clinically relevant risk groups.  
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 Hence assessing the DECAF score at the time of admission in 
AECOPD helps in decision regarding  
1. Early escalation of care 
2. Deciding the location of treatment – Intensive care or ward 
3. Determining the need for use of ventilator 
4. Deciding on end-of-life care 
5. Helps the physician in informing the patient and relatives regarding 
the prognosis and exacerbation related short term risks. 
  
 
 
    
 
 
 
 
 
  
111 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS 
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The major limitations of our study are: 
1). Lack of post hospital follow up data, which would be necessary 
for validation of predictive factors found in the present study. 
2). The number of female patients enrolled in the study was quite 
small, lesser than that expected. However since consecutive patients were 
recruited, this has to be considered as corresponding to what occurs in the 
real life setting. 
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ABBREVIATIONS 
 
AECOPD Acute Exacerbation of Chronic Obstructive Pulmonary 
Disease 
 
AF  Atrial Fibrillation 
 
COPD       Chronic Obstructive Pulmonary Disease 
 
DECAF  Dyspnea, Eosinopenia, Consolidation, Acidemia, 
Fibrillation. 
 
eMRCD  extended Medical Research Council Dyspnea Score 
 
FEV1 Forced Expiratory Volume in one second  
 
FVC Forced Vital Capacity 
 
MRCD Medical Research Council Dyspnea Score 
 
NPAE Non pneumonic Acute Exacerbation 
 
PNAE Pneumonic Acute Exacerbation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
PATIENT CONSENT FORM & INFORMATION SHEET 
Title of the Project 
The DECAF Score: Prognostication Scoring System for Patients Hospitalised 
with Acute Exacerbation of Chronic Obstructive Pulmonary Disease” 
 
Institution : Department of Thoracic Medicine, 
Madras Medical College, 
Chennai-600 003.  
Name                :     Date    : 
Age  :     IP No    : 
Sex  :     Project Patient No               : 
The details of the study have been provided to me in writing and explained to me in 
my own language and  the purpose of the study has been explained. 
I confirm that I have understood the above study and had the opportunity to ask 
questions. 
I understood that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. 
I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). 
I have been given an information sheet giving details of the study. 
I fully consent to participate in the above study regarding ‘Prognostication Scoring 
System for Patients Hospitalised with Acute Exacerbation of Chronic 
Obstructive Pulmonary Disease’. 
 
 
__________________________ 
Name of the Subject 
_____________ 
Signature 
___________ 
Date 
 
 
  
__________________________ 
Name of the Investigator 
_____________ 
Signature 
___________ 
Date 
 
 
  
 
 
 
  
 
 
Clinical Questionnaire Name: Age: Sex: IP/OP number: Presenting illness:   Dyspnea Scoring: Co morbidities: Smoking history: Clinical Examination:    Blood investigations: Complete blood count:   Absolute Eosinophil Count:  Arterial Blood Gas analysis:   Radiological investigations:    DECAF Score :  Date of Discharge: Duration of hospital stay: Clinical Outcome: 1. Improved   2. Status Quo 3. Mortality 
 
 
 
 
 
name  age  Sex co morbidity cor pulmonale dyspnea eosinopenia consolidation acidemia fibrillation DECAF score hospital stay outcome use of ventilator 
Thangadurai 64 male nil no 5b no yes no no 3 10 status quo no 
raman 56 male nil mild PHT 5a no yes no no 2 7 improved no 
susheela 75 female nil no 4 no no no no 0 4 improved no 
selvan 55 male DM,SHT no 5b no no no no 2 13 improved no 
venkatesan 69 male nil no 5a no no no no 1 5 improved  no 
vinayakam 60 male CAD no 5b no yes yes no 4 10 mortality yes 
abdul rashid 45 male connective tissue disorder mod PHT 5b no yes yes no 4 8 improved no 
subramani 65 male SHT severe pht 5b no yes yes no 4 2 improved no 
pooranam 67 female PT SEQUALAE mild PHT 4 no no no  no 0 4 improved  no 
govindraj 70 male SHT no 5a no no yes no 2 13 improved no 
syed thajudeen 75 male PT SEQUALAE no 5b no yes no no 3 9 improved no 
damodaran 50 male PT SEQUALAE mild pht 5b no yes yes no 4 6 mortality yes 
singaram 72 male PT SEQUALAE no 5a no no no no 1 4 improved  no 
selvaraj 71 male SHT no 5a no no yes no 3 10 improved no 
yakur sherif 70 male SHT mild PHT 5a no no no no 1 4 improved  no 
Sengini 72 male CKD no 5a no no no no 1 6 improved no 
purushothaman 73 male Nil no 5b no no yes yes 4 5 mortality no 
ekambaram 60 male nil mild PHT 5a no yes no no 2 5 status quo no 
masilamani 75 male SHT no 5a no no no no 1 6 improved no 
 perumal 60 male PT SEQUALAE mild PHT 5b no yes yes no 4 13 mortality no 
periasamy pillai 70 male nil no 5a yes no yes no 3 10 improved no 
meena 70 female SHT no 5a no no no no 1 10 improved no 
subramani 73 male pt sequalae, ca stomach mild PHT 4 no no no no 0 14 improved no 
 krishnan 62 male nil no 5a yes yes no no 3 5 improved no 
rose 50 female PT SEQUALAE no 5a no yes no no 2 5 improved no 
babu 60 male PT SEQUALAE no 5b yes yes yes no 5 11 improved yes 
balu 50 male nil no 5b no no no no 2 11 improved no 
sekar 47 male osa severe pht 5b no no yes no 3 12 status quo yes 
ananda sekaar 64 male nil no 5b yes no no no 3 4 improved no 
alagarsamy 63 male nil no 5a no no yes no 2 10 improved no 
nagarathinam 77 male nil no 5b no no yes yes 4 13 improved no 
navaneetham 50 female SLE mod PHT 5b no yes yes no 4 18 mortality yes 
 
 
vijayakumar 45 male PT SEQUALAE no 5b no no no no 2 6 improved no 
 
 
ganesan 75 male CAD no 4 no no no no 0 6 improved no 
srinivasan 46 male nil no 5a no no no no 1 4 improved no 
murali 44 male nil no 5b no no no no 1 13 improved no 
aadhi 47 male PT SEQUALAE no 5a no no yes no 2 13 improved no 
sarangan 40 male nil no 5a yes no no no 2 7 improved no 
vajram 50 male hypersenstivity pneumonitis severe pht 5b no yes yes no 4 10 mortality yes 
murugan 30 male PT SEQUALAE no 5a no yes no no 2 11 improved no 
iyappan 47 male PT SEQUALAE no 4 no no no no 0 9 improved no 
thiruneelakandan 67 male nil severe pht 5b no yes yes no 4 11 mortality yes 
mani 59 male PT SEQUALAE no 5b no yes no no 3 13 improved no 
kasiammal 47 female nil no 5b no yes yes no 4 9 mortality yes 
rajendran 60 male ckd no 5a no no no no 1 9 improved no 
kaliyan 65 male nil no 5a no no no no 1 4 improved no 
thanigavel 42 male nil severe pht 5b no no yes no 3 13 improved yes 
sundar raj 51 male nil severe pht 5b no yes yes yes 5 15 mortality yes 
karuna 58 male nil no 5b no no no yes 2 6 improved no 
ayyakannu 60 male nil mild PHT 5b no yes no no 3 8 status quo no 
sultan 63 male OSA no 5b no yes no no 3 4 status quo no 
chellan 55 male PT SEQUALAE severe pht 5b no yes no no 3 7 improved yes 
raguraman   male pt seualae, seizure severe pht 5b yes no no no 3 9 improved no 
pachaiappan 66 male nil no 5b no yes yes no 4 5 improved no 
balu 54 male cad no 4 no yes no no 1 4 improved no 
banu 55 female hypersenstivity pneumonitis mild PHT 5b no yes yes no 4 17 improved no 
natarajan 54 male nil no 5b no yes yes no 4 2 mortality yes 
jeyaraman 65 male PT SEQUALAE no 4 no no no no 0 5 improved no 
vellammal 55 female nil no 5b no no no no 2 8 improved no 
narayanan 63 male nil no 5a no no no no 1 8 improved no 
soundiah 72 male PTB no 4 no yes no no 1 3 improved no 
kumar 47 male CAD severe pht 4 no no no no 0 5 improved no 
chandrahasn 68 male nil no 4 no no no no 0 4 improved no 
muniandi 68 male nil no 4 no no no no 0 3 improved no 
akbar ali 67 male nil no 4 no no no no 0 5 improved no 
 
 
 
 
 
feroz khan 61 male nil no 4 no no no no 0 4 improved no 
dayalan 55 male nil no 4 no no no no 0 4 improved no 
rajendran 47 male nil no 4 no no no no 0 5 improved no 
thangavel 52 male nil no 4 no no no no 0 4 improved no 
radhakrishnan 65 male PT SEQUALAE no 5a no yes no no 2 5 improved no  
yamunapathi 60 male pt sequalae,  no 4 no no no no 0 4 improved no 
chellapa reddy 60 male nil no 5b no no no no 2 18 improved yes 
Duraisamy 72 male hypersenstivity pneumonitis severe pht  5b no no yes no 3 7 improved no 
karuppiah 61 male nil no 4 no no no no 0 4 improved no 
 padmanaban 82 male nil no 4 no no no no 0 4 improved no 
samikannu 47 male nil no 4 no no no no 0 5 improved no 
jeganathan 57 male nil no 4 no no no no 0 4 improved no 
munusamy 52 male nil no 4 no no no no 0 4 improved no 
thiruselvam 74 male connective tissue disorder no 4 no no no no 0 3 improved no 
thulasi 45 female nil no 4 no no no no 0 4 improved no 
sugumar 46 male PT SEQUALAE severe pht 5b no yes yes no 4 13 improved yes 
anbuchelian 68 male PT sequale no 4 no no no no 0 4 improved no 
kasi  48 male nil no 4 no no no no 0 4 improved no 
krishnasamy 74 male pt sequalae no 4 no no no no 0 3 improved no 
velu 53 male nil no 4 no no no no 0 3 improved no 
nathan 56 male nil no 4 no no no no 0 5 improved no 
elancheralathan 68 male nil no 4 no no no no 0 4 improved no 
ignasi muthu 57 male nil no 4 no no no no 0 4 improved   
kuppan 75 male nil no 4 no no no no 0 3 improved no 
nallakannu 67 male nil no 4 no no no no 0 3 improved no 
 
